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The manifestation of HIV-1 infection is different in children and adults. Most of the 
children who acquire HIV perinatally progress to disease within the first two years of 
life, while adults can remain asymptomatic for up to ten years. However, a small 
minority group of children can control the virus for years in the absence of 
antiretroviral therapy. We characterized CD8+ T cell responses critical for the 
containment of HIV infection in a cohort of infants HIV infected from birth using IFN-
γ ELISPOT, multicolour flow cytometry and viral sequencing of the Gag protein. We 
investigated whether the age at the time of infection, specificity and functionality of the 
generated responses, genetic make up and the maternal immune responses to HIV, 
influenced disease progression in the child.  
 
We found that the majority of in-utero infected infants mounted CD8+ T cell responses 
from the first days of life. In contrast to chronically infected children or adults, the 
specificity of the initial response in acutely infected infants was directed towards Env 
and Rev proteins and CD4+ T cell responses were minimal during the first 6 months of 
life. Slow progression to disease was associated with possession of one of the 
protective HLA-B alleles by either the mother or the child (P=0.007) and targeting of 
Gag epitopes presented by the protective HLA-B alleles. Mothers who expressed 
protective alleles but whose children did not possess these alleles, transmitted less fit 
viruses that benefited their children. Furthermore, slow progressor children had more 
polyfunctional CD8+ T cell responses in early infection when compared to rapid 
xvii 
 
progressors (P=0.05). The ability of infants to induce CD8+ T cell responses early in 
life is encouraging for vaccine interventions. The differences in the specificity of the 
initial responses between adults and children, insufficient priming of these responses as 
a result of minimal CD4+ T cell help during infancy and possession of non-protective 
HLA alleles shared between mother and child, may explain the rapid disease 
progression generally noted in most infants. However, slow progression to disease in 
the minority group of children may be attributed to functional capacity of the CD8+ T 
cells generated by the child, mediation by protective HLA alleles, acquisition of low 
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CHAPTER 1 : OVERVIEW OF ADAPTIVE T CELL 




1.1. HIV/AIDS: THE GLOBAL PERSPECTIVE  
Globally, an estimated 33 million people were living with human immunodeficiency 
virus (HIV) in 2007, of which 2.7 million were newly infected (UNAIDS, 2008). The 
number of acquired immune deficiency syndrome (AIDS) related deaths since the 
discovery of HIV was 25 million at the end of 2007, and in the same year, 2 million 
people died of the disease. Sub-Saharan Africa still bears the most HIV burden 
accounting for 67% of all people living with the virus and 75% of AIDS deaths in 2007 
(UNAIDS, 2008), Fig 1.1.  
 






HIV prevalence is highest in young women between the ages of 15 and 24, accounting 
for an estimated 45% of new infections worldwide. Children younger than 15 years 
accounted for 370,000 new infections and 2 million children were living with HIV in 
2007 (UNAIDS, 2008).  
  
1.2. HIV/AIDS EPIDEMIC IN SOUTH AFRICA  
An estimated 5.2 million South Africans were living with HIV in 2008 and over 
250,000 people died of AIDS in 2008 (South Africa Report, 2008, UNAIDS, 2008). 
The national prevalence is around 11% and varies by province, with the Western Cape 
(3.8%) and Northern Cape (5.9%) being the least affected, while Mpumalanga and 
KwaZulu-Natal are the most affected at 15.4% and 15.8% respectively. In children 
younger than 15 years, an estimated 280,000 were living with HIV in  South Africa in 
2007 (UNAIDS, 2008). In the absence of antiretroviral therapy (ART), HIV is the 
leading cause of death in children younger than 2 years in developing countries (Dabis 
et al., 2001, Obimbo et al., 2004). Mother-to-child-transmission accounts for the 
majority of infections in children while heterosexual transmission is predominant in 
young women of child bearing age; and HIV seroprevalence among antenatal women in 




Figure 1.2. Distribution of HIV prevalence by province in antenatal clinic attendees, 
South Africa, 2008. (South Africa Report, 2008).  
 
1.3 HIV-1 STRUCTURE AND REPLICATION  
1.3.1 Structure 
HIV is a retrovirus, an enveloped virus that replicates in a host cell by copying its RNA 
into a complementary DNA using reverse transcriptase encoded by the virus. The 
integration of the viral genome into the host genome is then mediated by integrase 
together with host cellular factors, allowing for many copies to be made in the host 
cells (Smith and Daniel, 2006). HIV encodes nine proteins; 3 major structural 
polyproteins, Gag, Pol and Env are required for the formation of new virus particles 
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and are common to all retroviruses, accessory proteins Vif, Vpr, Vpu and Nef found 
within the virion and the accessory proteins Tat and Rev are essential for regulatory 
functions and virion assembly (Frankel and Young, 1998). 
 
The Gag gene encodes a polyprotein precursor Pr55Gag that is cleaved by viral 
protease to mature Gag proteins p17 matrix (MA), capsid (p24), p7 nucleocapsid (NC) 
and p6. In addition, 2 spacer peptides, p1 and p2 located between capsid and 
nucleocapsid and between nucleocapsid and p6 are also generated upon Pr55Gag 
processing (Fig 1.3), (Accola et al., 1998, Freed, 2001). The synthesis of Gag and Gag-
Pol polyprotein Pr55Gag takes place in the cytosolic polysome before transportation to 
the plasma membrane (Murakami, 2008). The matrix, composed of viral protein p17, 
surrounds the capsid and ensures the integrity of the virion particle. The matrix is 
important for the incorporation of viral surface glycoproteins into virions (Dorfman et 
al., 1994, Yu et al., 1992), targeting of Gag to plasma membrane and early post entry 
events (Freed, 1998). The capsid forms the characteristic cone shaped shell of the 
mature virion that encloses the viral genomic RNA (Gelderblom et al., 1987) and plays 
a crucial role in virus assembly, maturation and post entry steps (Freed, 1998). 
The nucleocapsid, found in the core tightly associated with the viral RNA (Meric et al., 
1984), is required for the encapsidation and dimerization of the viral RNA, membrane 
binding and for stabilization of the preintegration complex and transcription. It also 
functions as a nucleic chaperone enabling refolding of nucleic acid molecules to more 















Figure 1.3. Schematic representation of the HIV-1 genome (top) and virion organization 





The proline-rich protein p6, located at the C-terminus of Gag is essential for the release 
of assembled virions from the cell surface (Gottlinger et al., 1991) and production of 
the Vpr protein (Kondo and Gottlinger, 1996, Paxton et al., 1993). The single stranded 
RNA is tightly bound to the nucleocapsid protein p7 and enzymes such as reverse 
transcriptase (RT), protease (PR), ribonuclease and integrase (IN) important for virion 
development.  
 
The pol gene is synthesized as part of Gag-Pol fusion due to the lack of the initiation 
codon, resulting in overlap and shift of the pol gene in the minus 1 reading frame with 
gag. Pr160GagPol is cleaved by viral protease to produce viral enzymes reverse 
transcriptase, protease and integrase, (Fig 1.3), (Freed, 2001, Hill et al., 2005). Reverse 
transcriptase catalyses the conversion of single stranded RNA into double stranded 
DNA early post infection while integrase catalyzes the insertion of linear double 
stranded viral DNA into the host cell chromosome (Hill et al., 2005). Protease cleaves 
the Gag and Gag-Pol polyproteins and allows conformational changes within the 
particle to produce mature infectious viruses (Frankel and Young, 1998).  
 
Synthesis of the Env glycoproteins gp160 takes place in the endoplasmic reticulum and 
these proteins are then transported via the secretory pathway to the plasma membrane 
(Murakami, 2008). The Envelope (Env) glycoproteins are produced as a polyprotein 
gp160, which is heavily glycosylated and cleaved by cellular protease into surface 
subunit (SU) gp120 and transmembrane subunit (TM) gp41 (Chan and Kim, 1998, 
Freed, 2001). gp120 determines interaction with the CD4 receptor and co-receptor 
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(either CXCR4 or CCR5) found on susceptible cells such as T lymphocytes and 
macrophages, this binding to target cell receptors activates gp41 to undergo a 
conformational change to a fusion-active state. gp41 anchors the gp120/gp41 complex 
to the membrane and facilitates membrane fusion between viral and host lipid bilayers 
during virus entry (Chan and Kim, 1998, Freed, 2001). In addition to the 3 structural 
proteins, the HIV-1 virus encodes 2 regulatory proteins Tat and Rev and accessory 
proteins Vpu, Vpr, Nef, Vif which are not essential in gene expression but important in 
viral infectivity, replication and contribute to the spread of the virus and disease onset. 
Transcriptional transactivator (Tat) is critical for activated transcription from HIV-1 
long terminal repeat (LTR) and contributes to apoptosis through induction of 
mitochondrial permeabilization, while regulator of gene expression (Rev) mediates the 
transport of viral mRNAs from the nucleus to the cytoplasm (Seelamgari et al., 2004). 
 
Negative regulatory factor (Nef) down regulates CD4 through rapid endocytosis from 
plasma membrane and MHC class I molecules from cell surface by protecting infected 
cells from cytotoxic T cell (CTL) recognition (Seelamgari et al., 2004). Viral protein R 
(Vpr) is essential for the transport of preintegration complex into the nucleus of 
infected cells and also induces cell cycle arrest in the G2 phase of the cell cycle. It is 
also involved in nuclear localization, apoptosis and has been shown to induce a 
proinflammatory cytokine tumour necrosis factor (TNF), known to activate HIV-1 
expression and replication (Freed, 2001, Nakamura et al., 2002, Seelamgari et al., 
2004). Recent data suggest that amino acid polymorphisms in specific residues in Vpr 
may affect epitopes significantly and contribute to the escape of the virus (Srinivasan et 
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al., 2008). Viral protein U (Vpu), is important in the late stages of infection in that it 
enhances the release of viral particles by counteracting host restriction imposed by 
tetherin (Neil et al., 2008, Nomaguchi et al., 2008). Vpu also promotes the degradation 
of CD4 and down regulates cell-surface expression of the CD4 receptor (Seelamgari et 
al., 2004) and also promotes the apoptosis of HIV-1 infected CD4+ T cells (Akari et al., 
2001). Viral infectivity factor (Vif) is expressed late in infection and is localized in the 
cytoplasm (Goncalves et al., 1994, Karczewski and Strebel, 1996). Vif increases the 
stability and assembly of virion cores and reverse transcriptase complexes and may 
prevent premature degradation upon viral entry (Ohagen and Gabuzda, 2000). The 
critical role of Vif is to suppress the function of APOBEC3G and APOBEC3F, which 
are host proteins important to its anti-viral function (Malim, 2009, Swanson and Malim, 
2008).  
 
1.3.2. HIV-1 Replication 
The HIV replication cycle can be summarized in six steps as illustrated in Fig 1.4; 1) 
binding and entry; 2) uncoating; 3) reverse transcription; 4) provirus integration; 5) 
virus protein synthesis and assembly and 6) budding (Fanales-Belasio et al., 2010). 
Entry of HIV-1 into target cells is mediated by the Env protein. The env gene encodes a 
polyprotein gp160 that is cleaved by cellular protease to yield the surface subunit 
gp120 and the transmembrane protein gp41 required for viral infectivity. Viral entry 
process begins when the viral surface envelope protein gp120 binds specifically to 
CD4; this interaction changes the conformation of gp120 which then increases the 
coreceptor affinity. A ternary complex composed of gp120, CD4 and coreceptor forms; 
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conformational changes in gp41 eventually trigger pore fusion formation between the 
virion lipid bilayer and the host cell plasma membrane releasing the viral core into the 
cytoplasm, (Freed, 2001, Gomez and Hope, 2005).  
 
The fusion process is carried out by the “fusion peptide” located at the amino terminus 
of gp41 by insertion of gp41/CD4/receptor complex directly into the target membrane 
at an early step of fusion process. Following fusion, the uncoating process takes place, 
during which the viral RNA undergoes the reverse transcription process and a 
preintegration complex is formed.  
 
During this process, the capsid is lost, while some matrix, nucleocapsid, pol-encoded 
enzymes reverse transcriptase and integrase and accessory protein Vpr remain 
associated as part of a high molecular weigh complex. In this process, the reverse 
transcriptase converts RNA genome into double stranded DNA before transportation of 
the preintegration complex to the cell nucleus (Freed, 1998, Freed, 2001), where the 





Figure 1.4. Schematic representation of the HIV-1 replication cycle (Fanales-Belasio et al., 
2010). 
 
The integrated provirus is then transcribed leading to the synthesis of viral RNAs which 
are transported to the cytoplasm. Translation of the mRNAs ultimately encodes the full 
complement of structural, regulatory and accessory proteins used to direct virus 
replication. The assembly process is mediated by the gag-precursor polyprotein 
Pr55Gag as it has determinants that target it to the plasma membrane, bind the 
membrane and encapsidate the viral genome. The Gag precursor also interacts with 
Gag-Pol precursor and the assembled Gag-protein complex induces membrane 
curvature leading to formation of a bud (Freed, 1998, Freed, 2001).  
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The budding process follows assembly and involves the incorporation of Env 
glycoproteins into new virus particles and is completed when the particles are released 
or pinched off from the plasma membrane. Maturation occurs during or shortly after the 
release of virions from the plasma membrane where the viral protease cleaves the Gag 
and Gag-Pol polyprotein precursors to generate mature Gag and Pol proteins. This 
leads to structural rearrangements that eventually generate mature infectious virions 
capable of initiating a new round of infection (Freed, 1998, Freed, 2001). The 
therapeutic approach of HIV/AIDS is through the use of different classes of 
antiretroviral drugs administered as a combination regimen that act at different stages 
of the HIV life cycle. Currently licensed and available classes of drugs include entry 
inhibitors, reverse transcriptase inhibitors, protease inhibitors and integrase inhibitors, 
named according to the phase of the HIV life cycle they inhibit.  
 
1.4. THE NATURAL RESPONSE TO HIV-1 INFECTION  
HIV-1 infection is characterized by an initial burst of high viral load, CD4+ T cell 
destruction and eventually stabilization to a viral set point indicative of the immune 
system’s partially successful attempt to fight off the virus in the absence of 
antiretroviral treatment. The mechanisms underlying the establishment of viral set point 
few months after acute infection are poorly understood, but may involve the interplay 
between host immune responses and viral replication (Fig 1.5). The viral load levels 
generally rebound to the same set point following discontinuation of ART and the viral 
set point may be a good predictor of the rate of disease progression; the higher the set 
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point, the more rapid the immunologic progression to disease (Hatano et al., 2000, 
Lyles et al., 2000). 
 
Studies from individuals with known dates of seroconversion have shown that it takes a 
median period of 10 years from the time of infection to onset of disease (Alcabes et al., 
1993, Pantaleo et al., 1993). The outcome of disease may vary amongst individuals; 
some individuals may mount immune responses able to control viral replication and 
remain clinically asymptomatic with minimal CD4+ T cell loss and very low to 
undetectable viral loads even up to 12 years of infection, while some individuals may 
fail to control virus replication with a rapid CD4 count decline and may develop AIDS 
within months to a few years of acquiring HIV infection (Cao et al., 1995, Pantaleo et 
al., 1995, Paranjape, 2005). Several mechanisms including host genetic factors, age, 
virulence of the infecting strain, co-infection with other microbes, and immunological 
factors may influence HIV disease progression (Fauci, 1993, Pantaleo et al., 1993).  
 
However, the adaptive immune response is thought to be the most critical component of 
the immune system in the control of HIV infection. Evidence of the importance of 
CD8+ T cells in viral control has been demonstrated in animal models, where CD8+ T 
cell depletion is associated with a dramatic increase in viral load in SIV infected 














Figure 1.5. Representation of a typical course of HIV-1 infection showing CD8+ and 
CD4+ T cell dynamics and viral load changes over the time of infection (Munier and 
Kelleher, 2007). 
 
In humans, the protective role of CD8+ T cell responses has been similarly 
demonstrated by the temporal association of the CD8+ T cell response with a decline in 
plasma viraemia following acute infection (Rosenberg et al., 2000), (Fig 1.5). Also, 
virus-specific CD4+ T cell responses are critical for the maintenance of effective CD8+ 
T cell function (Altfeld and Rosenberg, 2000, Kalams et al., 1999, Rosenberg et al., 
1997). Thus immunologic control of viraemia may depend on a strong CD4+ T cell 
helper and CD8+ T cell responses. 
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1.4.1. The role of CD8+ T cell response in adult HIV-1 Infection 
Cytotoxic T lymphocytes (CTLs) also referred to as CD8+ T cells, recognize HIV 
infected cells through HIV viral antigenic epitopes (8-11 amino acid in length), that 
have been processed intracellularly and are expressed on antigen presenting cells in 
conjunction with class I major histocompatibility complex (MHC) molecules and β2 
microglobulin (Paranjape, 2005). The CD8+ T cell receptor recognizes the class I 
MHC, β2 microglobulin, viral peptide complex which triggers the CD8+ T cell to lyse 
the infected cell (Gandhi and Walker, 2002). Thus the CD8+ T cell response in an 
individual depends on HLA haplotype and the alleles expressed by the individual. 
 
There is substantial evidence of the role HIV-specific CD8+ T cells play in combating 
viral replication during the acute infection phase. First, there is massive expansion of 
the CD8+ T cells in acute infection (Pantaleo et al., 1994) which coincides with the 
appearance of HIV-specific CD8+ T cells and a decline in plasma viraemia (Koup et 
al., 1994). Second, CD8+ T cells taken from patients with HIV-1 were able to inhibit 
viral replication in autologous CD4+ T cells in vitro (Yang et al., 1996). Third, 
depletion of CD8+ T cells from SIV infected animals using monoclonal antibodies 
results in failure to clear SIV viraemia after infection and rapid progression to disease 
(Schmitz et al., 1999).  
 
Lastly, the immune selection pressure exerted by the CD8+ T cell response following 
early infection in animal and human infection suggest that the virus can rapidly mutate 
to escape CD8+ T cell recognition and control (Allen et al., 2000, Borrow et al., 1997). 
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The factors influencing the effectiveness of the CD8+ T cell response in controlling 
viral replication and in subsequently establishing the different viral set points in 
individuals remains poorly understood. It is suggested that the initial CD8+ T cell 
responses are low in magnitude and narrowly directed toward viral proteins such as 
Vpr, Nef, Tat and Env (Altfeld et al., 2001, Cao et al., 2003, Dalod et al., 1999). These 
responses are regarded as the most effective in controlling viral replication as they have 
the greatest antiviral activity (Cao et al., 2003); however, in the absence of treatment, 
the initial CD8+ T cell response continues to evolve and are less effective in further 
reducing viral load. 
 
In contrast, the role of the CD8+ T cell response in chronic infection is still 
controversial as a large majority of patients lose viral control despite the presence of 
HIV-specific IFN-γ producing CD8+ T cells with high avidity or antigen specific 
CD8+ T cells that are able to recognize viral proteins such as Env, Gag and Pol (Addo 
et al., 2003, Draenert et al., 2004, Frahm et al., 2004, Gea-Banacloche et al., 2000). 
Furthermore, conflicting results have been reported between HIV-specific CD8+ T cell 
responses and viral load in chronic infection (Betts et al., 2001, Betts et al., 1999, 
Migueles and Connors, 2001, Ogg et al., 1998, Shankar et al., 2000). On the other hand, 
CD8+ T cell responses from therapy naïve long term non-progressors (LTNPs) have a 
greater capacity to proliferate coupled with perforin and IL-2 production and in 
addition display strong proliferative CD4+ T cell responses to Gag antigens, 
attributable to enhancement of the CD8+ T cell effector function (Migueles et al., 2002, 
Rosenberg et al., 1997, Zaunders et al., 2004). Also, recent data showed that LTNPs 
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displayed polyfunctional CD8+ T cells than progressors, suggesting that the quality of 
the CD8+ T cell response may be important for viral control (Betts et al., 2006). Thus, 
HIV-specific CD8+ T cells may become ineffective as the disease progresses and mere 
quantification with assays that measure IFN-γ production alone may not be adequate to 
understand mechanisms underlying this dysfunction in chronic infection. 
 
Several mechanisms have been implicated in CD8+ T cell dysfunction. First, the 
depletion of essential CD4+ T helper cells by HIV may be an important cause for 
progressive loss of CD8+ T cell function since the CD4+ T helper cells are critical in 
providing effective CD8+ T cell function (Cardin et al., 1996, Gloster et al., 2004). 
Continuous viral replication and generalized immune activation may result in 
functional T cell defects, T cell exhaustion and activation-induced apoptosis of HIV-
specific CD8+ T cells (Brenchley et al., 2003, Lichterfeld et al., 2004a, Streeck et al., 
2008). The immature state of CD8+ T cells rather than end-stage effector cells may also 
affect the CD8+ T cell response (Chakraborty, 2005, Kostense et al., 2002). Finally, 
mutations of viral sequences recognized by CD8+ T cells can evade host recognition by 
CD8+ T cell responses resulting in uncontrolled viral replication (Geels et al., 2003, 
Goulder and Watkins, 2008). 
 
1.4.2. CD4+ T cell responses in adult HIV-1 Infection 
The hallmark of HIV-1 infection is the progressive decline in the number of CD4+ T 
cells. Activated CD4+ T helper cells are the main target of HIV and are killed by 
infection and HIV induced apoptosis (Cottrez et al., 1997, Groux et al., 1992, Levy, 
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1993), leading to a decrease in CD4 counts and defects in CD4+ T cell function (Musey 
et al., 1999). The CD4+ T cell recognize peptide antigens in association with class II 
MHC molecules after endocytosis of exogenous proteins by antigen presenting cells. 
The peptide-class II MHC complex is then recognized by the CD4+ T cell receptor and 
leads to activation of CD4+ T cells (Gandhi and Walker, 2002). Activated CD4+ T 
helper cells can mediate Th1 response by producing IL-2 and IFN-γ which are 
important for maintaining an effective CD8+ T cell response. The majority of anti-
HIV-specific CD4+ T cell responses are detectable during primary infection in 
response to high viral load (Altfeld et al., 2001, Kalams et al., 1999, Rosenberg et al., 
1997) and these responses may persist in chronic infection (Ramduth et al., 2005, 
Scriba et al., 2005). In the absence of ART, long term non-progressors maintain 
proliferating CD4+ T cell responses (Rosenberg et al., 1997, Schwartz et al., 1994). 
Strong T helper response were associated with strong CD8+ T cell responses implying 
that immunologic control in HIV infection may in part depend on both strong CTL and 
T helper responses. 
 
With continuous viral replication, the CD4+ T cell response may produce IFN-γ but 
loose the ability to produce IL-2 or to proliferate (Iyasere et al., 2003, Younes et al., 
2003), which is associated with lack of viral control. In addition, CD4+ T cells 
senescence has also been reported in HIV infection (Palmer et al., 2005). Thus, T cell 
control of HIV replication depends on the host immunological response and the ability 
of T cells to proliferate in response to viral antigen exposure, while maintaining low 




1.5. MOTHER-TO-CHILD-TRANSMISSION  
Around 70,000 babies are born HIV infected every year in South Africa, most of whom 
acquired the virus during pregnancy, birth or breastfeeding (WHO, 2009). Without any 
intervention, there is a 20-45% chance that a mother will transmit HIV to their new-
borns (De Cock et al., 2000). The use of combination antiretroviral therapy given to the 
mother during pregnancy and to the child immediately after birth can reduce the risk of 
mother-to-child-transmission to less than 2%. Such interventions together with obstetric 
management and use of alternative infant feeding methods have made vertical 
transmission relatively rare in developed countries (EuropeanCollaborativeStudy, 
2005). In developing countries, around 45% of HIV infected women received drugs to 
protect their children from infection during 2008 (WHO/UNAIDS/UNICEF, 2009, 
WHO, 2009), most women are not reached by prevention of mother-to-child-
transmission (pMTCT) services due to lack of adequate health-care infrastructures and 
access to antiretroviral drugs or are unaware of their HIV status (De Cock et al., 2002, 
Menu et al., 1999).  
 
Previously, single-dose nevirapine regimen to the mother at labour and to the child at 
birth according to the HIVNET-012 protocol has been widely used as a standard 
regimen for perinatal prevention due to its low cost, simple administration and high 
efficacy of the regimen (Abrams, 2004, Guay et al., 1999).  However, the development 
of mutations associated with nevirapine resistance (Eshleman et al., 2001) and potential 
negative effect these mutations may have on the future use of the drug led to the current 
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use of long-course antiretroviral regimens that are more effective in reducing in utero 
and intrapartum transmissions (Scarlatti, 2004). 
 
 The recent South African guidelines require that mothers be given zidovudine (AZT) 
from 14 weeks of pregnancy until labour and single dose nevirapine during labour; to 
the infant single dose nevirapine from birth upto 6 weeks of life (National Department 
of Health, 2010). However, these guidelines fall short of the international standards as 
the World Health Organization (WHO) recommends that mothers take AZT and 
lamivudine (3TC) during and after birth to prevent transmission of the virus to the child 
and also as a cover tail strategy to reduce the risk of nevirapine resistance (WHO, 
2006). Although suboptimal when compared to international standards, scaling up from 
nevirapine only using regimen to dual therapy is challenging in resource-limited 
settings but can be achieved to reduce transmission to rates as low as those seen in 
developed countries (Amornwichet et al., 2002, Geddes et al., 2008, Plipat et al., 2007, 
Tonwe-Gold et al., 2007). 
 
1.5.1. Timing of infection and determinants of MTCT 
MTCT can take place during pregnancy, at birth and through breastfeeding; however, 
the majority of infants acquire HIV infection despite repeated exposure to the virus 
even in the absence of antiretroviral drugs. In utero transmission accounts for an 
estimated 20-30% of vertical transmission (Abel, 2009) and is also associated with 
rapid disease progression in the infected infants (Dickover et al., 1998, Kuhn et al., 
1999). Although transmission can occur throughout pregnancy, the majority of HIV-1 
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transmission occurs in the last trimester of gestation (Kourtis et al., 2001, Rouzioux et 
al., 1993). Generally, the placenta is an efficient barrier allowing for few in utero 
infections. However, MTCT in utero most likely occur through direct infection of the 
plancental or trophoblastic cells, although infection of the trophoblastic cells does not 
always result in infection of the fetus (Lee et al., 1997, Menu et al., 1999, Zachar et al., 
1994). 
 
Intrapartum transmission can occur during delivery by maternofoetal blood 
transfusions, amniotic fluid, vaginal secretions as a result of prolonged membrane 
ruptures or postnatal by breast milk. It is estimated that breastmilk transmissions bear 
the bulk of all MTCT cases ranging from 25-50% (Luzuriaga, 2007, Luzuriaga et al., 
2006). It is hypothesized that the risk of breast milk transmission is the greatest during 
the first 6 weeks of life since viral load levels in human breast milk are the highest in 
the first few days after delivery (Rousseau et al., 2004), however, the risk of 
transmission remains high throughout the breastfeeding period (Nduati et al., 2000, 
Abrams, 2004, Coutsoudis et al., 2004).  
 
Several risk factors influence MTCT transmission of HIV to the infant; high maternal 
plasma viral load, low CD4 counts or advanced maternal disease state, prolonged 
membrane rupture before delivery and increased duration of breastfeeding. In addition, 
child and maternal HLA mediated immune responses and viral characteristics also 
determine susceptibility to HIV infection (Abrams, 2004).  The encouraging aspect is 
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that the use of antiretroviral drugs has been shown to minimize the risk of transmission, 
often alleviating the impact of these well-known risk factors. 
 
1.5.2. Viral Kinetics in Paediatric HIV-1 Infection 
Acute HIV-1 infection in adults is followed by the development of HIV-specific CD8+ 
T cell responses and temporal decline in viraemia from an average of 10 million copies 
to a median set-point of 30 000 copies/ml (Lyles et al., 1999, Rosenberg et al., 2000). 
In paediatric HIV-1 infection, there is no substantial decrease in viral load, instead 
viraemia remains over 100,000 to a million copies/ml in the first year of life and does 
not reach viral set point until after the first 2 or more years of life in surviving children, 
(Fig 1.6), (Abrams et al., 1998, Richardson et al., 2003, Shearer et al., 1997).  
 
In the absence of antiretroviral therapy (ART) intervention, 45-59% of HIV-infected 
children in developed countries will die by the age of 2 years (Dabis et al., 2001, 
Obimbo et al., 2004, Spira et al., 1999), while the remaining children will progress 
slowly to AIDS by the age of 5-6 years (Barnhart et al., 1996, Blanche et al., 1990). It 
is still unclear whether the differences in viral kinetics following infection in 
paediatrics and adults contribute to rapid disease progression in children; however, it is 






Figure 1.6. Schematic representation of viral load and levels of CD8+ T cell activity (CTL) 
in therapy naïve adult and paediatric HIV infection (Prendergast et al., 2007). 
 
 
1.5.3. Immune Control in Paediatric HIV-1 Infection 
In contrast to adults, several factors have been proposed to accelerate disease 
progression in children. First, the immature immune system at the time of infection 
may be incapable of generating immune responses essential for viral containment. 
Continued viral replication in infancy could be a result of the size of the pool of host 
cells permissive to viral replication, exposure of the thymus to HIV-1 mediated 
destruction at a time of active thymopoiesis (Chakraborty, 2005, Nahmias et al., 1998) 
or in some cases, destruction of the immune system happens before responses can be 




Second, the genetic similarity between mother and child may be disadvantageous to the 
child as children acquire a virus with a history of encounter with maternal immune 
responses. Thus, the lack of immune control in the mother following adaptation of the 
virus to maternal HLA alleles shared with the child may result in failure to control the 
virus by the child (Tiemessen and Kuhn, 2006). The prognosis is different in children 
who acquire the virus through blood transfusions or who share protective alleles with 
their fathers (Frederick et al., 1994, Kuhn et al., 2004). Third, infected children are 
likely to inherit HLA alleles associated with poor control of HIV from their mothers 
than uninfected children since MTCT is associated with maternal viral load 
(Prendergast et al., 2007, Sperling et al., 1996). Fourth, although CD8+ T cell 
responses are detectable in infants, these responses are low in frequency and 
inconsistent during early life (Froebel et al., 1994, Luzuriaga et al., 1995, Buseyne et 
al., 1998) in comparison to older children and adults and do not offer immediate 
clinical benefit (Lohman et al., 2005, Riviere and Buseyne, 1998). Furthermore, CD4+ 
T helper responses, important for the maintenance of effective CD8+ T cell responses 
are of low magnitude during early infancy (Feeney et al., 2004, Thobakgale et al., 2007, 
Wasik et al., 2000, Huang et al., 2008), but are detectable in older children, although at 
lower frequencies than reported in adults (Pitcher et al., 1999). The lack of CD4+ T cell 
help may compromise CD8+ effector function in infants and contribute to the low 





There is evidence that CD8+ T cell responses may mediate control in paediatric HIV-1 
infection. For example, HLA alleles such as B*2705 and B*5701 known to mediate 
control in adult infection have been shown to mediate non-progression in paediatric 
infection and the development of mutations in key epitopes presented by these alleles is 
followed by loss of control (Feeney et al., 2005, Feeney et al., 2004). However, there is 
also evidence of fitness cost to the virus if the mutations are within the conserved 
regions such as Gag, thus benefiting the child in the context of MTCT transmission 
(Leslie et al., 2004, Thobakgale et al., 2009). There are reports that CD8+ T cell 
responses exert selection pressure in known CD8+ T cell epitopes within the first few 
months of life suggesting that these responses may be effective (Pillay et al., 2005).  
 
Taken together, these reports demonstrate that HLA class I alleles influence disease 
progression in paediatric infection through generation of CD8+ T cell responses or 
transmission of low-fitness viruses as has been shown in adult infection (Martinez-
Picado et al., 2006). The sustained detection of CD4+ T helper activity in children with 
delayed disease progression highlights the importance of these cells in paediatric HIV-1 
pathogenesis (Chakraborty et al., 2005, Wasik et al., 2000). HIV-1 may directly kill 
thymic cells required for normal thermocyte development (Stanley et al., 1993, 
Valentin et al., 1994). However, unlike in adults, the thymus is very active in children, 
the recovery of T cells is through the thymic production of new naïve T cells and 
generation of new T cells clones with various specificities capable of responding to 




1.6. STUDY AIMS AND OBJECTIVES  
The mechanisms underlying the lack of viral control following paediatric HIV-1 
infection are poorly understood. The timing for the development of adaptive T cell 
responses remains controversial, and where detected, the effect of these responses in 
combating viral replication is not well established. The factors that mediate slow or 
long-term-non progression to disease in children are also not well studied in children. A 
cohort of 63 acutely HIV-1 infected infants was established and followed up over 3-4 
years to address the following aims and objectives:  
 
To determine the timing of virus-specific T cell development and the specificity of the 
CD8+ T cell response following acute HIV infection in infants 
 
To determine whether or not the genetic background (HLA) of the mother or child will 
have a bearing on disease outcome in the child 
 
To determine T cell functionality by longitudinally assessing T cell polyfunctionality, 
activation and senescence in a group of slow and rapid progressor children from birth 






1.7. OUTLINE OF THESIS  
A detailed overview of the HIV epidemic and replication, determinants of transmission 
from mother-to child and the role played by T cell responses in the control of adult 
versus paediatric HIV-1 infection is covered in the first part of Chapter 1. The next 
chapters describe a series of investigations undertaken to understand the timing of the 
earliest detectable T cell responses in infants following acute infection and the factors 
that determine slow versus rapid progression to disease over time in these children. 
Chapter 2 examined HIV-infected infants born to infected mothers and monitored the 
age of development and specificity of the HIV-specific CD8+ T cell responses using a 
panel of overlapping peptides spanning the entire HIV clade-C proteome. In addition, 
the CD4+ and CD8+ T cell responses were compared in infants with early infection 
versus older children with established HIV-1 infection.  
 
Chapter 3 tested the hypothesis that HIV-infected children are likely to progress 
slowly to disease if they or the transmitting mother possess protective HLA alleles that 
are not shared between mother and child or if the mother transmits low-fitness virus to 
the child. The HLA-type, CD8+ T cell responses and viral sequences of mother-child 
pairs who were monitored from birth were investigated. Chapter 4 further explored T 
cell functional characteristics that distinguished children with rapid versus slow disease 
progression within the same cohort of children after 3-4 years of longitudinal follow-up 
from time of birth. This was done by assessment of T cell quality by investigating T 
cell polyfunctionality, activation and senescence from early through to chronic 
infection in a group of identified rapid and slow progressor children. Chapter 5 
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summarizes the key findings of these studies with reference to previous literature and 
suggests future directions for paediatric research in T cell immunolgy. These studies 
demonstrate that like adults, children have the capacity to generate CD8+ T cell 












CHAPTER 2 : HIV-SPECIFIC CD8+ T CELL 
ACTIVITY IS DETECTABLE FROM BIRTH IN 
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An association between HIV-specific CD8+ and CD4+ T cell responses and control of 
viral replication has been well documented in acute adult infection (Gloster et al., 2004, 
Goulder et al., 1997, Goulder and Watkins, 2004, Borrow et al., 1994, Allen et al., 
2004) but it is less clearly established what role CD8+ T cells play in control of HIV in 
acute paediatric infection, which occurs both in utero and intrapartum. In adults, the 
appearance of HIV-specific CD8+ T cell immune responses in acute infection is 
temporally associated with a rapid decline in viremia from an average of 10 million 
copies/ml at peak to a median set-point of 30,000 copies/ml (Lyles et al., 1999, 
Rosenberg et al., 2000). In paediatric infection there is typically no such rapid decline 
in viremia following acute infection, viral loads remaining in an excess of 100,000 
copies/ml over the first year of life, and only decreasing slowly over the next 2-3 years 
of life in survivors (Richardson et al., 2003, Shearer et al., 1997). 
 
A potential explanation for the absence of a dramatic decline in viremia in early 
paediatric infection is either low-frequency HIV-specific CD8+ T-cell activity and/or 
ineffective CD8+ T-cell activity in infancy. Previous studies of limited numbers of 
HIV-infected infants have demonstrated that HIV-specific CD8+ T-cell responses can 
be detected at low frequency in some infants (Buseyne et al., 1998, Luzuriaga et al., 
1995, Scott et al., 2001). Moreover, when detected in infancy, the CD8+ T cell 
responses generated had no immediate benefit in clinical outcome (Buseyne et al., 
1998, Lohman et al., 2005, Riviere and Buseyne, 1998), and no studies have compared 
in utero, intrapartum and chronic paediatric infection. Recent reports that CD8+ T cell 
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responses in infants can exert selection pressure in vivo in known CD8+ T cell epitopes 
within the first few months of life (Feeney et al., 2005, Leslie et al., 2005, Pillay et al., 
2005) suggest that in some instances, at least, these responses may be functional. In 
addition, slow progression to disease has been well described in children who express 
HLA-B*27 or HLA-B*57 (Feeney et al., 2005, Feeney et al., 2004), suggesting that 
CD8+ T cell responses can be important in paediatric infection as in adult infection. 
 
The aim of these studies was to examine a large cohort of infants born to HIV infected 
mothers, to determine both the age at which HIV-specific CD8+ T cell responses are 
induced in infected infants, and the specificity of these responses using a panel of 
overlapping peptides spanning all the HIV proteins. These studies were undertaken in 
Durban, South Africa, a country in which its estimated that there are >100 newly 
infected infants born each day (http://www.avert.org/worldstats.htm). 
 
2.2. MATERIALS AND METHODS 
2.2.1. Study Subjects   
Sixty-three HIV-1 infected infants born to HIV-positive mothers were enrolled from St 
Mary’s and Prince Mshiyeni Hospitals in Durban, South Africa from 2003-2005 (Table 
2.1). HIV-1 seropositive mothers were recruited during the last trimester of pregnancy 
and a single dose of Nevirapine was given to the mother during labour and to the infant 
within 48 hrs of birth, according to the HIVNET-012 Protocol (Guay et al., 1999, 
Jackson et al., 2003). A total of 719 mothers were enrolled and screened, 740 infants 
were born to the mothers; 623 infants were uninfected, 41 were untraceable and only 75 
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were infected. Sixty-three of the 75 infants met the clinical criteria for enrollment into 
the study. Exclusion criteria comprised prematurity, intrauterine growth restriction and 
congenital anomaly (Mphatswe et al., 2007). 
 
Forty-five HIV-1-positive, antiretroviral therapy naïve children with chronic infection 
between ages of 2 and 12yrs were recruited from the Paediatric HIV outpatient clinic at 
King Edward VIII Hospital and McCord Hospital, both in Durban, South Africa. The 
median absolute CD4 count of this cohort of children with chronic HIV infection was 
559, with a median CD4% of 17, and a median viral load of 110,000 copies/ml (Table 
2.2). The mothers gave written informed consent for participation of their children both 
studies. These studies were approved by all the participating Institutional Review 
Boards.  
 
2.2.2. Diagnosis of HIV-1 Infection in Infants 
Infants were diagnosed as HIV-infected following detection of plasma HIV RNA by 
RNA-PCR (Roche Amplicor Assay). Blood was collected on day 1 and day 28 of life. 
A positive plasma viral load (>400 RNA copies/ml) on day 1 or day 28 was followed 
by a confirmation test before enrollment of the infant into the study. Infants with 
detectable virus on day 1 were defined as intra-uterine (IU) infected (n=44), and infants 
with undetectable virus on day 1 but with detectable virus on day 28 were defined as 
intrapartum (IP) infected (n=19). Since the majority of infants were breast-fed, it is 





2.2.3. Viral Load and CD4 Measurement 
Plasma viral loads were measured using either the Roche Amplicor Monitor Assay 
detection limit of 400 HIV-1 RNA copies/ml plasma,) or the Roche Ultra sensitive 
assay detection limit of 50 RNA copies/ml plasma), according to the manufacturer’s 
instructions. CD4 counts were determined from fresh whole blood using Tru-Count 
technology and analyzed on a four-color Flow cytometer (Becton Dickinson) according 
to the manufacturer’s instructions.  
 
2.2.4. Isolation of PBMCs 
Blood was collected in EDTA tubes and processed within 6hrs of collection. Peripheral 
blood mononuclear cells (PBMCs) were isolated from whole blood using the Ficoll-
Histopaque (Sigma, St Louis, Mo) density gradient centrifugation and used fresh in 
ELISPOT assays.   
 
2.2.5. Synthetic HIV-1 Peptides 
A panel of 410 overlapping peptides (18mers with a 10-amino acid overlap) spanning 
the entire HIV-1 clade C consensus sequence were synthesized on an automated 





2.2.6. ELISPOT Assays 
Screening for T-cell responses was done ex vivo using the Interferon-γ ELISPOT assay 
as previously described (Kiepiela et al., 2004). The individually recognized peptides 
within the pools were determined by the use of a second Elispot assay. 
 
Freshly isolated PBMCs were plated in 96-well polyvinylidene difluoride-backed plates 
(MAIP S45; Millipore) that had been previously coated with 100 µl of anti-human IFN-
γ mAb 1-D1k (0.5 µg/ml; Mabtech) overnight at 4 0C. Peptides were added at a final 
concentration of 2µg/ml to a 96-well plate with 100 µl of R10 medium at 50 000 or 100 
000 cells/well. Negative controls with cells and medium only were run in quadruplicate 
along with two positive controls containing phytohaemoagglutinin. The plate with 
contents was incubated overnight at 37 0C, 5% CO2 and then processed. Following 
overnight incubation, the plate was washed with cold PBS and 0.5 ug/ml of IFN-γ mAb 
biotinylated secondary antibody (7-B6-1, Mabtech) was added for 90 minutes in the 
dark at room temperature. The plate was then washed with cold PBS, and 0.5μg/ml of 
streptavidin-alkaline phosphatase conjugate antibody (Mabtech) was added for 45 
minutes in the dark at room temperature. IFN-γ producing cells were noted by direct 
visualization of the plate following development with alkaline phosphatase color 
reagents (Bio-Rad). 
The IFN-γ secreting cells were quantified by counting the number of spots per well 
using an automated Elispot plate reader (AID ELISPOT reader system; Autoimmun 
Diagnostika GmbH, Strasburg, Germany).  Results were expressed as number of spot 
forming cells (SFC) per million PBMC after subtractions of background wells. A 
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response was defined as positive, using previously adopted criteria (Addo et al., 2003, 
Kiepiela et al., 2004), if it was ≥100 SFC/million PBMCs and >3 standard deviations 
above the mean of 4 background wells containing PBMCs but no peptide. The mean 
background levels in all assays were always less than 120 SFC/106 cells, with a range 
of 0-120 SFC/106 cells.  
 
Quantitation of CD8+ T cell responses towards each HIV protein was undertaken from 
the Elispot assays as follows: following subtraction of the background in each well, the 
number of SFC for each well containing peptides within a particular protein were 
summated; only positive wells with responses ≥100 SFCs were used to calculate 
responses to each protein. Wells with responses < 100 SFCs were treated as negative 
and were assigned a value of 90 SFCs for statistical analyses. To calculate the relative 
contribution of each protein to the total CD8+ HIV-specific response for each study 
subject, the total response to all 9 HIV proteins was summated, and the contribution of 
each individual protein derived by dividing the protein-specific response by the total 
response. Any protein-specific response that was <100 SFC/million PBMC represented 




2.2.7. Flow cytometric intracellular cytokine staining 
Freshly isolated PBMCs (0.5 x 106) were incubated at 370C, 5% CO2 for 90 min with 
peptide pools at a final concentration of 2 µg/ml per peptide following stimulation with 
anti-CD28 and anti-CD49 antibodies (Becton Dickinson). Brefeldin (Sigma) was added 
and cells were incubated for a further 4.5hrs at 370C, 5% CO2. Cells were then stained 
with anti-human allophycocyanin (APC)-conjugated CD8 and anti-human 
phycoerythroerythrin (PE)-conjugated CD4 antibodies (Becton Dickinson), washed, 
fixed and permeabilized as previously described (Ramduth et al., 2005) before adding 
anti-IFN-γ FITC, IL-2 FITC or TNF-α FITC. Following 20 minutes incubation the cells 
were washed, resuspended in 200µl of PBS and acquired on a FACS-Calibur (Becton 
Dickinson). Duplicate negative controls with PBMCs alone together with a positive 
control containing PBMCs stimulated with phytohaemagglutin, were included in the 
assays. For the infant cohort, a minimum of 150 000 events were collected per subject, 
and a minimum of 100 000 events were collected for the chronic children cohort.   
 
The total CD4+ and CD8+ T cell responses were obtained after subtracting the mean of 
two negative controls. Reference ranges were obtained from intracellular cytokine 
staining for Gag interferon-gamma in a total of 23 HIV-uninfected infants between the 
ages of 1 week to 17M.  A response was considered positive if above 0.07% for CD8 
and above 0.02% for CD4 responses. Gag-specific CD8+ responses ranged from 0.00-




2.2.8. HLA Typing 
DNA for HLA typing was extracted using Puregene DNA isolation kit for blood 
(Gentra Systems, Minneapolis, Minn.) according to the manufacture’s instructions.  
HLA Class I typing was done by DNA PCR using sequence specific primers as 
previously described (Kiepiela et al., 2004).  
 
2.2.9. Statistical Analysis 
Fisher’s exact test was used to compare proportions of IU and IP infants with early 
detectable responses and also to compare the number of responders in acutely and 
chronically infected children. The Mann-Whitney test was used to compare differences 
in magnitude and contribution of each protein to the overall total response in the 9 HIV 
proteins targeted by both acute and chronic children. Mann-Whitney test was also used 






2.3.1. HIV-specific CD8+ T cell responses are detectable from day-1 of life in 
infected infants 
To determine whether in-utero HIV infection induces an adaptive immune response 
above the level of any response in exposed-uninfected infants, we enrolled 10 randomly 
selected HIV-infected mothers, and tested their newborn infants’ HIV-specific CD8+ T 
cell responses on day 1 of life, blind to diagnosis.  Three of 10 had detectable CD8+ T 
cell responses on day 1 of life, and all subsequently proved to be HIV-infected by 
plasma HIV RNA determination (Fig 2.1A). The remaining 7 subjects who all had 
undetectable CD8+ T cell responses (<100 SFC/million PBMC) proved to be HIV-
uninfected.  
 
In order to further define adaptive immune responses in acute infant infection, we 
studied an expanded cohort of infants who were HIV infected on day one of life 
(defined as in utero infected), and other infants who were HIV-negative on day-1 but 






















Figure 2.1. Early detection of CD8+ T cell responses in HIV-infected infants. (A). CD8+ T 
cell responses on day 1 of life in 10 infants born to HIV-positive mothers. (B). Detection of 
HIV-specific CTL responses in acutely infected infants. Infants were grouped by weeks 
depending on the earliest time the first assay could be done. For both plots, infants with 
CD8+ T cell responses above the horizontal dotted line (≥ 100 SFC/million PBMCs) were 
defined as to having positive responses, and those below, a negative response. Vertical 
dotted line divides intrauterine and intrapartum infected infants. Responses < 100 SFCs 
were assigned 90 SFCs and treated as negative. 
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A total of sixty-three infected infants were identified from 719 mothers enrolled in the 
study: 70% of these infants (44/63) were intra-uterine (IU) and 30% (19/63) 
intrapartum (IP) infected (Table 2.1). The initial IFN-γ Elispot assays were performed 
as soon after diagnosis as feasible, before antiretroviral therapy was initiated, at a 
median of 9 days of age (range 1-92 days) in IU-infected infants and at a median of 55 
days of age (range 31-105 days) in IP-infected infants (Fig 2.1B). CD8+ T cell 
responses were detectable in 39/63 infants (29 of 44 in IU infected; 10 of 19 IP 
infected). In 3 of these infants, all of whom had detectable responses, peptides within 
Env and Vif were not included in the assay because of paucity of PBMCs. HIV-specific 
CD8+ T cell responses were detected in 14 of 20 in utero infected infants tested within 
one week of birth, and the majority of IU-infected infants tested after 4 weeks of life 
had detectable responses (Fig 2.1B and data not shown). Overall, a greater proportion 
(29/44; 65%) of IU infected infants had detectable cellular immune responses 
compared to IP-infected infants (10/19, 52%; not significant) with a median follow up 
of the intrapartum infected infants of 52 days (range 31-105 days). By comparison, all 
of 45 chronically infected children had detectable CD8+ T cell responses when initially 
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2.3.2. Frequent targeting of Env in early paediatric infection and Nef in chronic 
infection 
To identify the proteins principally targeted in early and chronic paediatric infection, 
the magnitude of the responses to each of the nine HIV proteins were documented from 
the first time point at which assays were performed for the 36 acutely infected infants 
(Fig 2.2A) and 45 chronically infected children (median age of 6 years; Table 2.2, Fig 
2.2B), who had detectable responses upon comprehensive screening in ELISPOT 




Figure 2.2. Hierarchy of responses to HIV proteins  targeted by acute (A) and chronically 
(B) infected children. Analysis made from the 36 acutely infected infants (n=39, 3 
excluded due to insufficient cells to carry out full matrix screen) and 45 chronically 
infected children all of whom made responses to at least one of the 9 HIV proteins on the 
first ELISPOT assay. The first ELISPOT assay was undertaken in infants at a mean of 31 
days of age (range 1 day –105 days, IQR 7-46 days). The number of infants showing 
positive responses to each protein is shown in parentheses. Negative responses were 
assigned 90 SFC/million PBMC (dotted line): values ≥100 SFC/million were defined as 










001-AC Day 4 IU A0101/3001, B4201/8101, Cw1701/1801 75 <400 
021-AC Day 1 IU A0205/29, B4201/44  Cw0202/1701 18 23,900
046-AC Day 36 IP A3002/6801, B5802/5802, Cw0606/0602 36 18,100,00 
081-AC Day 92 IU A29/68, B1516/44, Cw03/07 44 92
094-AC Day 34 IU A2301/6801, B0702/5802, Cw0202/0602 41 >100,000 
097-AC Day 44 IP A0301/3601, B4501/5301, Cw04/1601 18 >750,000
102-AC Day 15 IU A2301/6602, B07/4201, Cw07/1701 47 >647,000 
114-AC Day 61 IP A03/24, B07/08, Cw07/07 57 4,190 
115-AC Day 42 IU A29/6801, B1503/5802, Cw04/0602 44 1,540
127-AC Day 33 IU A02/3402, B0801/1503, Cw02/04 46 436,000 
133-AC Day 31 IU A68/7408, B5802/8101, Cw04/0602 54 241,000
135-AC Day 69 IU A01/3002, B08/8101, Cw07/18 13 >750,000 
149-AC Day 21 IU A3001/8001, B1503/18, Cw0202/0202 51 948
188-AC Day 32 IP ND d ND 2,330, 000
197-AC Day 6 IU A3001/3402, B44/5802, Cw04/0602 42 1,500 
222-AC Day 26 IU A29/6802, B0702/1302,Cw0602/07 48 <400
227-AC Day 5 IU A0301/26, B1529/5201, Cw0202/07 ND 311 
241-AC Day 56 IP A23/23, B44/81  Cw0202/04 54 4, 820
251-AC Day 13 IU A29/6802, B1510/1516, Cw03/04 56 12,400 
268-AC Day 27 IU A3201/6802, B07/07, Cw0102/07 34 13,200
274-AC Day 4 IU A6601/8001, B18/4201, Cw0202/1701 45 40,400 
275-AC Day 55 IP A23/6601, B1503/5802, Cw0202/0602 27 3, 890 
284-AC Day 36 IU A3201/6801, B08/15, Cw04/07 38 3,030
298-AC Day 42 IU A29/6802, B13/14, Cw06/08 35 339,000 
304-AC Day 5 IU A3402/6802, B1510/44, Cw03/07 44 14,200
312-AC Day 84 IP A0301/6802, B1510/5802, Cw03/0602 27 3,690 
341-AC Day 64 IP A3002/3201, B1510/5802, Cw03/0602 13 1, 426, 000
344-AC Day 52 IP A29/6802, B44/5802, Cw0602/07 14 >750,000
349-AC Day 4 IU A2301/4301, B4501/5802, Cw0602/0602 ND 33,950 
355-AC Day 69 IP A01/0301, B0801/5802, Cw0602/07 15 15, 800
360-AC Day 47 IU A02/3601, B3601/53, Cw0602/04 18 4,040,000 
364-AC Day 23 IU A29/3002, B4102/44, Cw07/1701 34 87,200
380-AC Day 9 IU A2301/6801, B1510/1510, Cw03/08 56 16,100 
385-AC Day 105 IP A3001/3402, B1503/1503, Cw0202/0202 37 2,760
413-AC Day 4 IU A01/3201, B07/8101, Cw07/1801 ND 5,650 
423-AC Day 31 IP A2301/2301, B18/41, Cw04/1701 38 14,040,000 
433-AC Day 41 IU A4301/6801, B1503/5801, Cw0602, 18 33 357,000
435-AC Day 2 IU A02/3004, B4201/44, Cw0202/1701 45 91,400 
446-AC Day 26 IU A02/3001, B1503/4501, Cw0202/1601 20 3, 730,000
447-AC Day 63 IP A03/6802, B1401/4701, Cw0602/0802 34 8,860,000 
458-AC Day 41 IP A4301/6801, B1503/1510, Cw03/18 37 2,340,000
464-AC Day 44 IU A29/6802, B15/18, Cw0202/03 28 5,720,000 
468-AC Day 3 IU A0202/6801, B5703/5801, Cw06/07 51 5630 
496-AC Day 13 IU A0301/6801, B1503/5802, Cw0602/06 32 882,000
517-AC Day 31 IP A3002/6802, B1510/4201, Cw03/1701 39 2,300,000 
559-AC Day 4 IU A2301/6802, B0801/5801, Cw07/07 61 731
562-AC Day 10 IU A0205/3002, B1402/5801 Cw07/0802 36 2,580,000 
568-AC Day 33 IP A3001/6802, B07/18, Cw07/07 45 >750, 000
576-AC Day 4 IU A29/6802, B1401/44, Cw07/0802 48 94,500
579-AC Day 8 IU A0202/3001, B4201/5703, Cw0701/1701 35 9,333 
586-AC Day 10 IU A0101/6802, B1510/8101, Cw08/1801 45 997
590-AC Day 8 IU A02/68, B1503/5802, Cw0202/0602 33 >750,000 
600-AC Day 7 IU A26/3002, B0801/8101, Cw04/07 28 8, 490
637-AC Day 14  IU A29/6601, B1302/5802, Cw0602/0602 34 2,200 
639-AC Day 7 IU ND 31 31,600
641-AC Day 35 IP A2301/3002, B0801/4501, Cw07/1601 43 >750, 000 
675-AC Day 5 IU A30/6601, B3910/5802, Cw0602/12 49 2,040 
698-AC Day 6 IU A0205/24, B0702/1401, Cw07/08 52 1,150
720-AC  Day 1 IU A3001/30, B0702/18, Cw02/07 47 66,300 
729-AC Day 103 IP A29/6601, B1510/5802, Cw03/06 15 8,490
732-AC Day 6 IU A3002/6602, B4201/45, Cw1601/1701 33 21,800 
737-AC Day 69 IP A0205/3001, B1510/4201, Cw08/1701 8 4, 140, 000
766-AC Day 1 IU A03/3402, B5802/5802, Cw0602/0602 33 2,780,000 
 
  






a Time point of the initial Elispot assay in the Acute Infant Cohort. b Transmission type: 
IU (intrauterine), the viral load was detectable at >400 RNA copies/ml on the first day 
of life ; IP (intrapartum), the viral load was undetectable (<400) on day 1 of life but was 
detectable on day 28 of life. c Viral load measurement at the time-point of the initial 
ELISPOT assay, several days following intake of single-dose nevirapine (viral loads at 
birth for 001-AC, 081-AC, 221-AC and 227-AC were 1,370, 22,400, 142,000 and 
7,940 RNA copies/ml, respectively). The initial viral load test  for IU infants was done 
on a median of 1 day of life (range, day 0 to 7), and IP- infants were tested on a median 
28 of life (range, 28 to 36). None of the infants were on treatment at the time of the first 
ELISPOT assay. d ND-not determined. 
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Table 2.2. Characteristics of the cohort of chronically infected children at the time of the 








001-CC 5 A02/74, B1510/44, Cw0202/03 26 92,000 
002-CC 3 A29/74, B15/35, Cw04/04 23 14,000 
003-CC 2 A0301/2301, B1503/5802,Cw0202/0602 27 670,000 
004-CC 5 A24/68, B0702/1510, 0304/08 24 58000 
005-CC 2 A23/29, B08/44, Cw03/1403 23 35000 
006-CC 4 A02/29, B44/44, Cw07/07 8 320000 
007-CC 6 A23/29, B14/4201,Cw0802/1701 15 39000 
009-CC 2 A4301/6802, B15/15, Cw03/1801 20 210000 
010-CC 7 A29/3001, B4201/57, Cw07/1701 18 14000 
011-CC 6 A0301/3001, B1503/5802, Cw0202/0602 22 4200 
012-CC 3 A3001/6601, B4202/5802, Cw0602/1701 18 1000000 
013-CC 11 A02/29, B1302/1401, Cw0602/08 10 83000 
014-CC 6 A03/03, B4501/5802, Cw0602/06 12 12000 
015-CC 8 A2301/4301, B1503/5802, Cw0202/0602 16 84000 
016-CC 6 A01/3402, B1503/8101,Cw0202/1801 18 49000 
017-CC 2 A23/3203, B1503/1503, Cw0202/0202 17 70000 
018-CC 2 A02/2301, B1510/5801, Cw07/1601 24 170000 
019-CC 4 A23/66, B1510/5802,Cw0602/1601 29 220000 
020-CC 5 A0202/4301, B1503/5703, Cw07/18 13 120000 
021-CC 3 A2301/6802, B1510/44, Cw03/03 12 150000 
022-CC 7 A6802/7408, B14/41, Cw0802/1701 20 50000 
023-CC 7 A3001/3201, B5703/5802, Cw1801/0602 17 270000 
024-CC 5 A02/2301, B0801/1503, Cw02/04 26 230000 
025-CC 5 A3402/6802, B1503/44, Cw04/04 20 6600 
026-CC 5 A02/33, B1516/4201, Cw1601/1701 13 21000 
027-CC 11 A2301/3201, B1503/1503, Cw0202/03 22 71900 
028-CC 12 A23/6802, B0801/4201, Cw03/1701 17 4300 
029-CC 8 A23/23, B0801/1503, Cw0202/03 12 24000 
030-CC 5 A03/23, B0801/41, Cw07/1701 18 110000 
064-CC 8 A29/6802, B1510/4403, Cw0701/0304 4 1670000 
065-CC 8 A2301/74, B1503/5301, Cw0202/0401 8 1300000 
082-CC 10 A29/66, B58/5802, Cw0602/06 5 454000 
091-CC 4 A2301/4301, B1510/1503, Cw16/18 16 4060000 
094-CC 9 A2301/24, B07/07, Cw07/07 17 100000 
098-CC 8 A2301/3402, B0801/44, Cw0202/0701 23 123000 
110-CC 4 A29/6801, B0702/5802, Cw0602/07 14 123000 
118-CC 5 A02/33, B4501/53, Cw04/1601 15 647000 
167-CC 7 A2301/3402, B4201/44, Cw04/1701 25 34400 
184-CC 12 A0205/74, B5801/35, Cw04/07 6 233000 
185-CC 9 A29/74, B1503/1510, Cw0202/16 15 100000 
205-CC 6 A0301/29, B0801/44, Cw07/07 28 355000 
261-CC 7 A24/3402, B0801/44, Cw04/07 25 4820 
299-CC 10 A3002/4301, B08/1503, Cw0202/07 10 141000 
314-CC 7 A0205/3001, B1510/4201, Cw08/1701 12 280000 




There was a greater number of responders to Gag, Pol, Vif, Nef and Vpr (p=0.0011, 
0.0001, 0.0051, 0.0008, 0.0051 respectively, Fisher’s exact test) among chronically 
infected children compared to acutely infected infants. Further analysis confirmed a 
larger magnitude of responses to Gag, Pol, and Nef (p=0.0012, 0.0002, 0.0410 
respectively, Mann-Whitney test) in chronically infected compared to acutely infected 
children. There were no significant differences between acute and chronically infected 
children in responses to Vpu, Tat, Env and Rev.  
 
We next compared the proportional contribution of each protein to the overall total 
response per child in both acute and chronic paediatric infection (Fig 2.3A). The overall 
contribution of the Env and Rev response was greater in acute infection compared to 
that in chronically infected children (p<0.0001 and p=0.0074) and in chronically 
infected children the contribution of the Nef-specific response to the total response was 
greater than in acute infection (p=0.0027, Mann-Whitney test, Fig 2.3B). Of particular 
significance is the predominant targeting of Env in acute infection: in one-third (12/36) 
of infants Env was the dominant target, compared to 4% (2/45) of the chronically 






































































































Figure 2.3.A. Relative contribution of protein response to overall response in acute and 
chronic infection. Reanalysis of the same data shown in Fig 2.2 is used to show the 
contribution of each protein to the total HIV-specific response in the acute infants (top 
panel) and chronic children (bottom panel) who had significant responses on the first 
ELISPOT assay. B. Comparison of the contribution of response to different proteins in 
acute (A) and chronic HIV-infected paediatric children (C) with detectable responses. 
47 
 
To determine whether the initial responses observed in children are maintained over 
time we tracked the responses longitudinally in four infected infants (Fig 2.4). These 
were the only four of 20 followed longitudinally from birth that did not meet the 
clinical and immunological WHO criteria to receive HAART within the first 12 months 
of age.  Two of the infants, 349-AC and 447-AC, illustrate the initially high 
contribution to the total HIV-specific response made by Env-specific CD8+ T cells in 
early paediatric infection. 447-AC required HAART after 14 months of life. 349-AC 
initially had dominant Env responses which decreased over the first 12 months and 
were later replaced by Gag and Pol-specific responses, development of the latter 
coinciding with a significant decrease in viral load (186,000 RNA copies/ml at 14 
months vs 2,280 RNA copies/ml at 24 months) and an increase in CD4 counts from 
30% at 14 months to 41% at 24 months without HAART (Fig 2.4A and B).  
 
133-AC who achieved successful control of viremia without the need for antiretroviral 
therapy (to 494 copies/ml and a CD4% of 29 at 31 months) showed a strongly 
dominant CD8+ Gag-specific response that persisted. Similarly, 517-AC initially had 
dominant Rev-specific responses that were soon replaced by dominant Gag-specific 
responses (Fig 2.4C and D).  Although viremia has remained high in this child (>1x106 
copies/ml), CD4% has also remained at high levels of >30%. However, these 4 
anecdotal cases are insufficient to allow an analysis of specificity of the CD8+ response 

















































































































































































































































Figure 2.4. Longitudinal measurement of CD8+ T cell responses, CD4 and Viral load in 
therapy naïve subjects A-349 (A) and A-447 (B), A-133 (C) and A-517 (D). The CD4 
counts and viral load measurements correspond to the time-points at which CD8+ T-cell 
responses were determined.  
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2.3.4. Weak CD4+ Gag-specific T cell activity in early paediatric infection 
Since CD8+ T cells require functional CD4+ T cell help to sustain their effector 
activity (Day and Walker, 2003) we examined Gag-specific CD8+ and CD4+ T cell 
activity in infants with early infection. We focused on Gag-specific responses since 
Gag is the dominant target for HIV-specific T-helper activity (Ramduth et al., 2005) 
and limitations on cell numbers precluded analysis of CD4+ T cell responses to non-
Gag proteins. In addition, Gag-specific CD4+ T cell responses have been detected in 
acute HIV infection of adults (Zaunders et al., 2005). Gag-specific responses were 
measured at 2, 4 and 6 months of age only, as 50 and 75% of the infants required 
HAART by 6 and 12 months of age, respectively. The infants with acute infection had 
detectable CD8+ T cell responses at all 3 time-points (median Gag-specific CD8+ T 
cell responses were 0.095, 0.155, and 0.14% at 2, 4 and 6 months, respectively). These 
responses were lower but did not differ significantly compared to those measured in 
chronically infected children (median 0.31% Fig 2.5A). In contrast, infants with acute 
infection had significantly lower CD4+ T cell responses at all time points than the 
chronically infected children, median Gag-specific CD4+ T cell responses being 0.01, 
0.01 and 0.02 CD4% at 2, 4 and 6 months, respectively, compared to 0.06% for 
chronically infected children (p<0.0001, <0.0001, <0.0008 respectively; Fig 2.5B).  
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Figure 2.5. A, B. Gag-specific CD8+ and CD4+ T cell responses in acute and chronic 
children by intracellular cytokine staining. C, D. Gag specific CD8+ and CD4+ IFN-γ, IL-
2 and TNF-α at 6 months of life in acute infected infants. All infants studied were 
antiretroviral therapy naïve at time of analysis. Dashed lines indicate the upper limit of 
responses detected from the same assays undertaken in 23 HIV-uninfected control infants 




We also compared Gag-specific CD8+ (Fig. 2.5C) and CD4+ (Fig. 2.5D) IFN-γ, IL-2 
and TNF-α production in the same of group of infants at 6 months of life. IL-2 and 
TNF-α responses were significantly less frequently detected than IFN-γ. In contrast, 
adults can generate substantial HIV-specific CD4+ IFN-γ and IL-2 responses during 
acute HIV infection (Zaunders et al., 2005), while chronic children on therapy show an 
increase in the frequency of IL-2 secreting CD4+ T cells (Correa et al., 2007). 
 
2.4. DISCUSSION 
These studies describe the early HIV-specific T-cell responses in paediatric infection. 
CD8+ T-cell responses are detectable from the first days of life in the majority (70%) 
of in utero infected infants. Responses were broadly directed, although Env specific 
CD8+ T-cell activity in particular contributed significantly more to the total HIV-
specific response in acute infected infants compared to chronically infected children 
(p<0.0001). Gag-specific CD4+ T-cell responses were weak or undetectable in the first 
6 months of life, contrasting with chronic paediatric or acute adult infection.  
 
Previous studies using non-comprehensive screening assays and in very limited 
numbers of subjects have demonstrated weak HIV-specific CD8+ T cell responses in 
infancy  (Luzuriaga et al., 1995, Luzuriaga et al., 1991). HIV-specific CTL have been 
detected in cord blood at birth previously (Luzuriaga et al., 1995) and HCMV-specific 
CTL in cord blood in utero (Marchant et al., 2003), indicating that immune responses to 
HIV can be detected very early in life. The studies described here demonstrate not only 
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that these early responses can arise, but that they are detectable in a high proportion 
(85%) of infants at the earliest time-point they were tested.  
  
Studies evaluating the specificity of the initial CD8+ T-cell response in infants infected 
with HIV have not been systematically undertaken, and the finding that Env-specific 
CD8+ T-cell activity contributes substantially to this initial response is of interest in 
relation to recent studies in adults indicating that Env-specific CD8+ T cell responses 
are associated with higher viral loads, and Gag-specific CD8+ T cell responses with 
lower viral loads (Borrow et al., 1994, Mphatswe et al., 2007, Riviere and Buseyne, 
1998). More studies will be needed to determine if this is related to the lack of a rapid 
reduction in viral load observed in early paediatric infection compared to early adult 
infection where Env makes a smaller contribution to the initial CD8+ T-cell responses 
(Lichterfeld et al., 2004b).   
 
It was not possible here to relate the specificity of the early CD8+ T cell response and 
progression in this cohort as two-thirds of the study subjects were enrolled onto a study 
of early HAART in paediatric HIV infection.  Of the 20 infants who did not receive 
early HAART, only 2 achieved viral loads of <100,000 in the first year. The finding of 
early CD8+ T cell responses combined with persistently high viral loads in the first 
year of life suggests that these CD8+ T cells are ineffective and additional functional 
studies will be needed to determine how this apparent dysfunction compares to that 
seen in adults (Borrow et al., 1994, Fauci et al., 1996). Comprehensive phenotypic 
analysis of CD8+ T cells in adults have demonstrated the association of polyfunctional 
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CD8+ T cells with control of viremia (Betts et al., 2006). These comprehensive 
analyses were not undertaken in these study infants, but the lack of IL-2 and TNF-α 
responses suggest that the majority of the CD8+ T cell responses detectable via the 
IFN-γ elispot assay may be monofunctional.   
 
Limitations imposed by cell numbers allowed only Gag-specific CD4+ T-cell responses 
to be assessed. Gag was chosen since it is consistently the dominant target for HIV-
specific CD4+ T-cell responses (Ramduth et al., 2005). The weak or undetectable Gag-
specific CD4+ T cell activity in acutely infected infants seen in this study also contrasts 
with acute adult infection, where adults present with high levels of CD4+ T cell 
responses during acute infection (Zaunders et al., 2005). In addition, Gag-specific 
CD4+ T cell activity has been reported in chronic infection in children >5 years old, 
who have spontaneously controlled viraemia without antiretroviral therapy (Feeney et 
al., 2003).  The marked absence of HIV-specific CD4+ T cell activity even to 6 months 
of age suggests a fundamental reason why CD8+ T cells in infected infants are 
ineffective (Gandhi and Walker, 2002, Lichterfeld et al., 2004a). These findings of a 
lack of HIV-specific CD4+ T cell activity are consistent with other studies (Luzuriaga 
et al., 1995), in one case showing minimal CD4+ T cell responses in HIV-infected 
children until 3-5 years of age (Sandberg et al., 2003). Furthermore, where detectable, 
HIV-specific CD4+ T cell responses have been reported as type 2 as opposed to type 1 
(Wasik et al., 1997, Wasik et al., 2000) and therefore less likely to support the 
induction and maintenance of HIV-specific CTL activity. Of concern, and again in 
contrast to what is observed in acute adult infection (Rosenberg et al., 2000), early 
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treatment with antiretroviral therapy in infected infants did not result in increased HIV-
specific CD4+ T cell responses (Ramduth et al., 2008). However, the extent to which 
these findings result from or cause the persistent high levels of viremia observed in 
early paediatric HIV infection is not known. 
 
The encouraging aspect of these data is that in-utero infected infants mount CD8+ T 
cell responses from the first day of life, while those infected intrapartum have 
detectable responses a month after infection. Although 85% of infected infants (in this 
cohort) met current WHO criteria to initiate HAART within 12 months of infection, it 
is also clear that a small minority (2/20) of infected infants showed viral loads of 
<10,000 and CD4% of >30% by 24 months of age. Thus, spontaneous-control of HIV 
is possible in paediatric HIV infection. Identification of greater numbers of ‘relative-
controller’ children will facilitate further definition of what constitutes an effective 
immune response in early paediatric HIV infection. Moreover, the fact that the neonatal 
immune system can generate adaptive immune responses to HIV provides important 
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HIV-specific CD8+ T cells play a central role in controlling viral replication (Goulder 
and Watkins, 2008). It is the specificity of the CD8+ T cell response, particularly to 
Gag, that is associated with low viral loads in HIV infection (Geldmacher et al., 2007, 
Zuniga et al., 2006, Kiepiela et al., 2007). Although immune control is undermined by 
the selection of viral mutations that prevent recognition by the CD8+ T cells, evasion of 
Gag-specific responses mediated by protective class I HLA-B alleles typically brings a 
reduction in viral replicative capacity, facilitating subsequent immune control of HIV 
(Leslie et al., 2004, Martinez-Picado et al., 2006, Brockman et al., 2007). The same 
principle has been demonstrated in studies of SIV infection (Kobayashi et al., 2005, 
Matano et al., 2004). 
 
Recent studies show that the class I HLA-B alleles that protect against disease 
progression present more Gag-specific CD8+ T-cell epitopes, and drive the selection of 
more Gag-specific escape mutations than those alleles that are associated with high 
viral loads (Matthews et al., 2008). These protective HLA-B alleles are not only 
beneficial to infected individuals expressing those alleles, but also benefit a recipient 
following transmission, since the transmitted virus carrying multiple Gag escape 
mutations may have substantially reduced fitness (Crawford et al., 2007, Chopera et al., 
2008, Goepfert et al., 2008). However, there is no benefit to the recipient if he/she 
shares the same protective allele as the donor, because the transmitted virus carries 
escape mutations in the Gag epitopes that would otherwise be expected to mediate 
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successful immune control in the recipient (Goepfert et al., 2008, Goulder et al., 
2001c).  
 
The sharing of HLA alleles between donor and recipient occurs frequently in mother-
to-child transmission (MTCT). The risk of MTCT is related to viral load in the mother, 
and high viral load is associated with non-protective alleles, such as HLA-B*18 and 
B*5802.  This may contribute in two distinct ways to the more rapid progression 
observed in paediatric HIV infection (Prendergast et al., 2008, Prendergast et al., 2007, 
Mphatswe et al., 2007). First, because infected children share 50% or more HLA alleles 
with the transmitting mother, they are less likely to carry protective HLA alleles than 
adults (Kiepiela et al., 2004). Thus, infected children as a group carry fewer protective 
HLA alleles, and a greater number of non-protective HLA alleles. Second, even when 
the child has a protective allele, such as HLA-B*27, this allele does not offer protection 
if the maternally transmitted virus carries escape mutations within the key Gag epitopes 
that are presented by the protective allele (Goulder et al., 2001c, Kuhn et al., 2004). 
  
However, it is clear that infected children who possess protective alleles, such as HLA-
B*27, or HLA-B*57, can achieve durable immune control of HIV infection if the virus 
transmitted from the mother is not pre-adapted to those alleles (Goulder et al., 2001b, 
Feeney et al., 2004). HIV-specific CD8+ T-cell responses are detectable from birth in 
infected infants (Thobakgale et al., 2007). Furthermore, as in adult infection (Chopera 
et al., 2008, Goepfert et al., 2008), HIV-infected children have the potential to benefit 
from transmission of low fitness viruses in the situation where the mother possesses 
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protective HLA alleles, and the child does not share those protective alleles. Mother-to-
child transmission of low fitness viruses encoding CD8+ T cell escape mutations has 
recently been documented (Prado et al., 2010, Sanchez-Merino et al., 2008).  
 
In this study, undertaken in Durban, South Africa, we set out to test the hypothesis that 
HIV-infected children are less likely to progress rapidly to disease if either the infected 
child or the transmitting mother possesses a protective HLA allele that is not shared. 
The HLA alleles most strongly associated with low viral loads and high CD4 counts in 
a cohort of >1200 HIV-infected adults in Durban are HLA-B*57 (B*5702 and 
B*5703), HLA-B*5801 and HLA-B*8101 (Kiepiela et al., 2004, Leslie et al., 2010). 
These four alleles all present Gag-specific CD8+ T-cell epitopes, and in each case the 
escape mutations selected in these epitopes reduce viral replicative capacity (Brockman 
et al., 2007, Chopera et al., 2008, Crawford et al., 2007, Martinez-Picado et al., 2006, 
Goepfert et al., 2008, Matthews et al., 2008).  
 
Analyzing a previously described cohort of 61 HIV-infected children in Durban 
(Mphatswe et al., 2007, Prendergast et al., 2008, Thobakgale et al., 2007), who were all 
followed from birth, we here address, first, the question of whether possession of any of 
these four alleles in either mother or child is associated with slower disease progression 
in the child; and, second, whether sharing of protective alleles by mother and child 
affects the ability of the child to make the Gag-specific CD8+ T cell responses 
restricted by the shared allele. 
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3.2. MATERIALS AND METHODS 
3.2.1. Study Subjects 
The paediatric study cohort has been previously described (Thobakgale et al., 2007, 
Prendergast et al., 2008). In brief, we enrolled 63 HIV-infected infants born to HIV-
infected mothers at St Mary’s and Prince Mshiyeni Hospitals in Durban, South Africa 
between 2003 and 2005. The HIV-1 seropositive mothers were recruited in the last 
trimester of pregnancy and received single dose nevirapine at the onset of labour and 
within 48 hours of birth to the child according to the HIVNET 012 protocol (Jackson et 
al., 2003, Guay et al., 1999). A total of 719 mothers were enrolled and screened and 
740 infants were born to the mothers, 75 were infected. Sixty-three of the 75 infants 
met the criteria for enrolment into the study. Exclusion criteria comprised prematurity, 
intrauterine growth restriction and congenital anomaly. 
 
Forty-three infants received short-term antiretroviral therapy (ART) immediately 
following diagnosis as part of a separate study investigating the effect of early, short-
term ART on disease outcome in paediatric infection. In this group, ART was 
discontinued after 12 months of continuous therapy or 18 months of interrupted 
therapy. The remaining 20 infants did not receive ART immediately but were followed 
up longitudinally. All infants enrolled onto the study received ART once World Health 
Organization (WHO) clinical or immunological criteria were met 
(http://www.who.int/hiv/pub/guidelines/WHOpaediatric.pdf). Taking into account 85% 
of HIV-infected children progress to CD4<20% by 1 year (Mphatswe et al., 2007), we 
here define slow-progression as failure to progress to meet WHO criteria to start ART 
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within 12 months in the absence of ART; progressors were those children who required 
ART within 12 months of life or within 12 months of discontinuing ART. 
 
HLA typing was obtained in 61 of the 63 enrolled mother-child pairs, two mother-child 
pairs withdrawing from the study shortly after enrolment. In addition HLA typing was 
undertaken antenatally on 236 HIV-infected mothers who did not subsequently 
transmit. 
 
The mothers gave written informed consent for participation of their children into the 
study. The study was approved by all the participating Institutional Review Boards.   
 
3.2.2. HLA Typing 
DNA for HLA typing was extracted using Puregene DNA isolation kit for blood 
(Gentra Systems, Minneapolis, Minn.) according to the manufacture’s instructions.  
HLA Class I typing was done by DNA PCR using sequence-specific primers as 
previously described  (Kiepiela et al., 2004). 
 
3.2.3. Synthetic HIV-1 Peptides 
A panel of 410 overlapping peptides (18mers with a 10-amino acid overlap) spanning 
the entire HIV-1 clade C consensus sequence were synthesized on an automated 
peptide synthesizer (MBS 396, Advanced ChemTech) and used in a matrix system in 
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screening assays (Kiepiela et al., 2004). Previously defined optimal peptides were also 
similarly synthesized. 
 
3.2.3. ELISPOT Assays 
Ex vivo measurement of T-cells for interferon gamma production was undertaken as 
previously reported (Kiepiela et al., 2004, Thobakgale et al., 2007). As previously 
described, specific responses of >100 SFC/million PBMCs were defined as significant. 
In the analyses shown in Fig 3.2C, responses less than this level were treated as zero or 
non-responsive. In addition, defined optimal peptides were also tested according to the 
corresponding HLA type of the subject. 
 
3.2.4. Viral Load and CD4 Measurement 
Plasma viral loads were measured using the Roche Amplicor Monitor Assay (version 
1.5) and CD4 counts were determined from fresh whole blood using Tru-Count 
technology as previously described (Thobakgale et al., 2007). 
 
3.2.5. Viral Sequencing 
Sequencing of HIV proviral DNA from mothers and children was undertaken as 
previously described (Leslie et al., 2004). Genomic DNA was extracted from peripheral 
blood mononuclear cell pellets; gag sequences were amplified by nested PCR, purified 
and directly sequenced.  
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3.2.6. Statistical Analysis 
Fisher’s Exact test was used to compare proportions defining progressor and slow 
progressor children, proportions of progressor and slow progressor children with 
protective and unshared HLA-B alleles. The same test was also used to determine the 
proportions of progressors and slow progressors with; ELISPOT responses to Gag 
epitopes, escape variants in epitopes presented by protective HLA-B alleles and 
proportions of escape variants in shared and unshared HLA-B alleles. The Odds ratio 
test was used to compare the number of sequence variations in children who made or 
did not make responses to the epitopes. The Mann-Whitney test was used to compare 
differences in the magnitude of Gag response in slow progressor and progressor 





3.3.1. Non-progression in infants is associated with unshared protective HLA B-
alleles in the mother or child 
Progression to disease is rapid in HIV-infected children, 85% of the children who did 
not receive ART immediately following diagnosis met the then WHO criteria to start 
ART (CD4 <20%) by 1 year (Mphatswe et al., 2007). For the purposes of this study, 
we defined slow-progression in these study subjects as failure to meet WHO treatment 
criteria within 12 months of birth, or within 12 months of cessation of ART in those 
who were treated with immediate, short-term ART after birth.  
 
Of the 61 studied mother-child pairs, one or more of the protective HLA alleles 
B*5702, B*5703, B*5801 or B*8101, was present in either the mother or child in 16 
pairs (Table 3.1). Ten of 61 transmitting mothers (16%) possessed one of the four 
protective HLA-B alleles, compared to 68 of 236 (29%) HLA-typed non-transmitting 
mothers (p=0.051, Fisher’s Exact test, Fig 3.1A). Slow-progression, as defined above, 






Table 3.1. Progressor and slow progressor mother-child pairs where child and/or mother 


















SLOW -PROGRESSOR CHILDREN (protective allele in 8 of 17 pairs)
CHILD MOTHER
Protective allele 133-C B*5802/ 8101 B*4201/5802
in child only
559-C B*0801/ 5801 B*0801/4101
586-C B*1510/ 8101 B*1510/5802
Protective allele 001-C B*4201/ 8101 B*4403/ 8101
in mother and child
468-C B*5703/5801 B*4403/ 5801
Protective allele 114-C B*0702/0801 B*0801/ 5702
in mother only
349-C B*4501/5802 B*4501/ 5702
568-C B*0702/1801 B*0702/ 8101
PROGRESSOR CHILDREN (protective allele in 8 of 44 pairs)
CHILD MOTHER
Protective allele 433-C B*1503/ 5801 B*1503/1516
in child only
562-C B*1402/ 5801 B*1402/1510
600-C B*0801/ 8101 B*0801/5802
Protective allele 135-C B*0801/ 8101 B*0702/ 8101
in mother and child
241-C B*4403/ 8101 B*4701/ 8101
413-C B*0701/ 8101 B*4403/ 8101
579-C B*4201/ 5703 B*1510/ 5703




















































































































































































Figure 3.1. Relative contribution of protective HLA-B alleles in mothers and children. 
Comparison of protective alleles expressed in (A) transmitting versus non-transmitting 
mothers and (B) progressor versus slow-progressor children. (C) Comparison of 
protective HLA-B alleles unshared between mother and child. 
 
In this slow-progressor group, a protective allele in either the mother or child was 
present in 8 of 17 pairs (47%), compared to 8 of the 44 progressor pairs (18%; p=0.047, 
Fisher’s Exact test, Fig 3.1B). Furthermore, a significantly higher proportion of slow-
progressor children had one of the protective HLA-B-alleles that were not shared by 
mother and child (7/17; 41%). In one pair, although the mother and child shared the 
protective B*5801 allele, the child (468-C) also carried B*5703 that was not shared 
with the mother.  In contrast, in only four of the 44 (9%) progressor mother-child pairs 
was one of the protective HLA B-alleles unshared by mother and child (p=0.007, 
Fisher’s Exact test, Fig 3.1C). These data therefore support the hypothesis that slow-
progression of HIV in this cohort of children is influenced by protective HLA-B-alleles 
in either the mother or child, in particular where the protective alleles are not shared by 
mother and child.  
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3.3.2. HIV-specific CD8+ T cell responses in the slow-progressor infants tends to 
target Gag epitopes presented by protective alleles B*57/B*5801/B*8101 
We next addressed the question of whether the slow-progressor infants possessing one 
of the 4 protective HLA-B alleles tended to generate detectable CD8+ T-cell responses 
to the Gag epitopes presented by these alleles. In the slow-progressor children 
expressing one of the protective HLA-B-alleles, 5/5 made IFN-γ ELISPOT responses to 
one or more of the Gag epitopes presented by these alleles compared to 3/7 progressor 
children (p=0.08, Fisher’s Exact test; Fig 3.2A,B). Overall, the slow-progressor 
children targeted 6/8 Gag epitopes presented by these alleles, compared to the 
progressor children in this category who targeted 3/11 Gag epitopes presented by these 
HLA-B alleles (p=0.07, Fisher’s Exact test; Fig 3.2A,B). We additionally analyzed 
Gag-specific CD8+ T-cell responses in slow progressor and progressor children 
without protective HLA-B alleles to optimal epitopes presented by their respective 
HLA alleles (Fig 3.2C). In the slow progressor children without protective alleles, 8/9 
made IFN-γ ELISPOT responses to one or more Gag epitopes, compared to 20/36 
progressor children (p=0.02, Fisher’s Exact test). In addition, the magnitude of the 
Gag-specific response in the slow progressor  
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KAFSPEVIPMF579-C B*5703† No response
TSTLQEQIAW579-C B*5703† No response











Figure 3.2. CD8+T cell responses to Gag epitopes in the first 12 months of life in children 
while not on HAART. Gag optimal epitopes presented by HLA-B*57/5801/8101 in (A) 
slow progressor and (B) progressor children with protective HLA-B alleles. (C) Gag 
optimal epitope responses in slow progressor and progressor children without protective 
HLA-B alleles. Symbols represent the magnitude of CD8+ T cell responses measured at 
different time-points by the ELISPOT assay in the first 12 months of life in children who 
deferred ART or in the first 12 months of cessation of ART in children who received 
immediate short-term ART. Magnitude of responses in panel C is shown by the median 
magnitude of the response for all time-points tested. A significant response was defined as 
a peptide-specific response of >100 SFC/million PBMCs (see Methods section 3.2.3). 
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children was higher (median, 6,539 SFC/million PBMC, range 0-14,350 SFC/million 
PBMC) than that of progressor children (164, range 0-16,428 SFC/million PBMC), 
(p=0.0177; Mann-Whitney test, Fig 3.2C). These data suggests that Gag-specific CD8+ 
T-cell responses tend to slow disease progression in HIV-infected infants, irrespective 
of the HLA clas I alleles presenting the Gag epitopes.  
 
3.3.3. CD8+ T-cell responses and MTCT of escape variants 
To investigate possible causes of the difference in responses to Gag epitopes presented 
by the protective HLA-B alleles that were observed in the progressor and slow-
progressor groups, we next addressed the question of whether failure to generate 
detectable CD8+ T-cell responses to the protective epitopes was related to transmission 
of variants by the mother (Fig 3.3). Virus was sequenced from the mother and child at 
the time point closest to transmission that was available (Fig 3.4). Variants in child 
sequences were observed in 2/9 cases where there were responses to the epitopes 
detected, compared to 5/10 cases where there were no responses detected (odds ratio 
2.25, p = ns; Fig 3.3A,B). Thus, whereas responses to epitopes are more likely to be 
observed if wild-type virus has been transmitted, in 50% of cases no response was 
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Figure 3.3. Mother and child Gag epitope sequence variation in (A) slow progressor and 
(B) progressor children.  
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Figure 3.4 Phylogenetic tree of mother and child sequences. Gag p24 nucleotide sequences 
from M (mother) before (a/n-antenatal) or after delivery and C (child) at different days 
(d) after infection were edited and aligned with SeqAlv2.0. Maximum-likelihood trees 
were constructed with GARLI (Genetic Algorithm for Rapid Likelihood Inference) 0.96 
program. Each colour represents a mother-child pair, and the scale represents 
substitutions per site.  
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3.3.4. Mother-child HLA sharing and MTCT of escape variants 
To investigate further the impact of HLA sharing of protective alleles by the child and 
the mother, we determined the frequency of transmitted variants within the p24 Gag 
epitopes (ISW9, KF11, TL9 and TW10) presented by the protective alleles HLA-
B*57/5801/8101. Sequences encoding the same epitopes, but in transmitting mothers 
not expressing the relevant alleles, served as controls. In sequences obtained from the 
mother as close to delivery as feasible (median 20 days prior to delivery; range 55 
antenatally to 432 days postnatally) 12/16 (75%) epitopes presented by the 
B*57/5801/8101 alleles and expressed in the transmitting mother contained mutations, 
compared to 5/24 (21%) in epitopes presented by the B*57/5801/8101 alleles and not 
expressed in the transmitting mother (p=0.001, Fisher’s Exact test, Fig 3.5A; Table 
3.2). Very similar findings resulted from analysis of sequences obtained from the child 
as close to diagnosis as feasible (median 31 days of age; range 1-447 days of age), 
(p=0.0001, Fig 3.5B). Thus, sharing of maternal alleles by the child is likely to 
contribute to failure of children to make responses to epitopes presented by protective 
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Mother or child possessing HLA-B allele presenting the epitope
Mother but not child possessing HLA-B allele presenting the epitope








Figure 3.5. Gag epitope variants in mothers (A) and children (B) where the mother either 
expressed or did not express the protective HLA B-alleles. 
 
Table 3.2. Deduced Gag epitope sequences in the 16 mother-child pairs where mother 




3.3.5. Mothers carrying protective HLA alleles transmit Gag variants reducing 
viral fitness 
Three of the 8 slow-progressor children and one of the eight progressor children had no 
protective HLA alleles themselves, but their mother possessed one. To address the 
question of whether the viruses transmitted by these mothers did in fact carry escape 
mutations in Gag that reduce viral fitness, virus from these mother-child pairs was 
sequenced from time-points as close as possible to transmission and tracked 
longitudinally to look for reversion of transmitted escape mutants in the HLA-
mismatched child (Fig 3.6).   
 
All the mothers transmitted escape variants to their children in each epitope presented 
by the protective maternal alleles. In all 3 cases where the child was defined as a slow-
progressor, reverting escape mutations were observed in all the epitopes, indicating an 
in vivo fitness cost to T242N and I147L in B*5702-negative 114-C (Fig 3.6A), to 
A146P and I247L in B*5702-negative 349-C (Fig 3.6B), to Q182S and T186S in 
B*8101-negative 568-C (Fig 3.6C). In the B*5801-negative progressor, 284-C, even 
though low fitness mutants were transmitted, such as A146P and T242N, reversion did 
not occur before CD4 decline to the point where the criterion for starting ART was 
reached rapidly. Thus, from analysis of this small number of mother-child pairs, it is 
clear that some benefit to the child is likely to accrue from the transmission of Gag 
escape variants within epitopes presented in the mother by protective HLA alleles such 
as B*5702/5703/5801/8101.  
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Figure 3.6. Evolution of escape Gag variants in HLA-B*5702 and HLA-B*8101 negative 
children  after transmission from HLA-B*5702 positive and HLA-B*8101 positive 
mothers. CD4%, viral loads and epitope sequence assessment in the four cases where 
mothers expressed protective HLA-B alleles and the child did not: (A) 114-C, (B) 349-C, 





While most HIV-infected children progress rapidly to disease following MTCT, a 
minority of children control the virus for years without the need for ART. These 
analyses of 61 HIV-infected children followed from birth highlight some of the factors 
associated with slow and rapid progression in children. Slow progression was 
associated with possession of either one or more of the known protective HLA B-
alleles, HLA-B*57, B*5801 or B*8101, particularly when these protective HLAs were 
not shared with their mothers (p=0.007). Slow progressors with or without protective 
HLA-B alleles were more likely to make HIV-specific CD8+ T-cell responses to Gag 
epitopes presented by the alleles, than progressors. Mothers expressing protective 
alleles were more likely to transmit escape variants within Gag epitopes presented by 
those alleles than mothers not expressing them (p=0.001). Reverting escape mutations 
were transmitted to, and subsequently reverted in all slow-progressing children whose 
mothers possessed protective HLA-B alleles. These data demonstrate the contribution 
of protective HLA-B alleles in either the mother or the child to slowing disease 
progression in paediatric infection.  
 
These data suggest that HIV-infected children can benefit from protective HLA-B 
alleles in the same way as infected adults, via the targeting of Gag epitopes presented 
by these alleles (Kiepiela et al., 2007, Matthews et al., 2008), and also may benefit 
from the acquisition of transmitted escape mutations as described in adult infection 




Although the presence of protective HLA-B alleles contributes to outcome in paediatric 
HIV infection, these studies illustrate that other factors are also operating to influence 
outcome. We have previously shown in studies from this same cohort that MTCT is 
related to maternal viral load (Mphatswe et al., 2007), and it would not be unexpected 
where factors other than the protective HLA-B alleles focused on in this study, play a 
role in determining maternal viral load. Nine of 17 slow-progressor children (53%) did 
not possess protective HLA-B alleles, and nor did their mother; and, of the progressor 
children, 8 of 44 (18%) carried a protective HLA-B allele or the mother did. Non-HLA-
associated factors likely to play a role would include non-HLA genetic factors  (Altfeld 
and Goulder, 2007, Shostakovich-Koretskaya et al., 2009), the presence of co-
infections by pathogens such as HCV, CMV, tuberculosis, and the concomitants of 
extreme poverty (Mphatswe et al., 2007). The humoral response constitutes another 
arm that may be responsible for mediating HIV-1 control and disease progression in the 
slow progressor group without detectable T cell responses, however the function of 
neutralizing antibody responses in delaying HIV-1 infection in perinatal transmission 
remains poorly understood. Nevertheless neutralizing antibodies are frequently detected 
during mother-to-child-transmission. Several reports in subtype A, B and C 
demonstrate that transmitted viruses in children are less susceptible to neutralization by 
their maternal antibodies (Dickover et al., 2006, Kliks et al., 1994, Wu et al., 2006). 
The inability to neutralize transmitted viral isolates suggests that there is preferential 
transmission of escape variants in mother-to-child-transmission setting. Even when 
there was sensitivity to neutralization, no correlation with disease progression was 
noted implying that neutralizing antibodies did not protect against disease progression 
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in children (Zhang et al., 2010). Overall, these data suggest that neutralizing antibodies 
may protect against mother to child HIV transmission but do not appear to significantly 
impact on pediatric HIV control.  However, further research is needed to evaluate 
factors that influence neutralization outcome of the viruses during perinatal 
transmission. 
 
A further factor reducing the apparent impact of HLA-B on viral fitness may be that 
mutations reducing viral fitness are transmitted by as many as 21% of mothers not 
themselves carrying the protective alleles (Table 3.2). In some cases it is possible that 
the father may have transmitted the allele to the child, and the variant to the mother, as 
previously described (Pillay et al., 2005). For example, subject 559-C carried B*5801 
that could be expected to select for mutations such as I247V in the epitope TW10, but 
the mother carried this mutant without having B*5801 herself. It is striking that a large 
proportion of the mother-child cohort carry HLA-B*57-associated mutations, but do 
not themselves possess B*57, for example 568-C/M. These data support the notion that 
these mutations, in spite of their having the capacity to revert in the absence of the 
restricting allele, nonetheless are seen at relatively high frequency even in HLA-
mismatched subjects (Kawashima et al., 2009). A potential reason for the persistence of 
mutations reducing viral fitness is that in some cases they are ‘neutralised’ by 
compensatory mutations. For example, in the anecdotal case of child 284-C, the 
mutations I223N/M228I/A248T/S252N were observed, that have been shown to 
contribute to reducing the fitness cost of T242N (Brockman et al., 2007).  In the child 
114-C, whose mother similarly transmitted T242N but, unlike 284-C, in whom 
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reversion did occur subsequent to transmission, the virus consistently at all 4 time-
points prior to reversion (days 439-773) showed wild type virus at all these positions. 
With such small numbers of study subjects in this category, these data are no more than 
suggestive explanations for lack of reversion over time seen in 284-C. A separate 
manuscript describing in detail the in vitro fitness of viruses from children in this 
cohort is has recently been published (Prado et al., 2010). 
 
A potentially important observation is the relative inability of CD8+ T-cell responses to 
be made by infected children even when they carry the protective HLA allele and the 
unmutated epitope has been transmitted (Figs 3.2-3.3). The reasons for this failure are 
unclear, but maternal well-being has a strong influence on paediatric disease 
progression (Prendergast et al., 2007).  For example, child 600-C, who had HLA-
B*8101, and whose virus encoded the unmutated TPQDLTNML epitope, made no 
detectable response to it (or to any other epitope – data not shown); the mother 600-M 
had an absolute CD4 count of 4 cells/mm3 (CD4% of 2%). 
 
An additional observation from the data presented in this study is the lack of precise 
correlation between transmission of escape mutants by the mother and either the ability 
of the child to make a response to the epitope or the disease outcome in the child. 
Previous studies (Goulder et al., 2001a) focusing on transmission of escape mutants 
within the HLA-B*27-restricted epitope, KK10 (KRWIILGLNK, Gag 263-272), 
suggested that escape variant transmission would result in no response being generated 
by the child, and more rapid progression in the child. Although the findings from this 
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present study are consistent with the B*27 study, the fact that some children can make a 
detectable response in spite of being infected by an epitope variant, and the fact that 
more rapid progression as a result of the MTCT of escape mutants within epitopes 
restricted by shared alleles is not always observed is, we would suggest, the result of 
two main factors.    
 
First, the impact of transmitted escape mutants on the child’s ability to make CD8+ T-
cell responses would depend on the particular escape mutants transmitted. In the case of 
the HLA-B*27-restricted epitope, KK10 (KRWIILGLNK, Gag 263-272), and the 
escape mutants transmitted referred to above (Goulder et al., 2001a), were shown to be 
non-binding mutants, which therefore prevented any response being made by a B*27-
positive child. However, where the mutant is still capable of binding to the HLA allele, 
such as T242N within the B*57/5801 TW10 epitope TSTLQEQIAW (Gag 240-249), a 
variant-specific response can be made by the child, as has been previously shown to be 
the case for the TW10 escape mutants (Feeney et al., 2005). A second possible 
explanation for the lack of a clearcut relationship between transmission of escape 
mutants and disease progression in the infant may relate to the impact on viral fitness of 
the escape mutants in question. Whereas the fitness costs of B*27-KK10 escape 
mutants at residue R264 are apparently fully compensated by compensatory mutations 
elsewhere in p24 Gag (Schneidewind et al., 2008, Schneidewind et al., 2009), this is not 
the case for the B*57/5801/8101 mutants focused on in this study, as is supported by 
the reversions in vivo shown in Fig 3.6. Thus, infants whose ability to generate a CD8+ 
T-cell response to a particular epitope may be hindered or abrogated by the 
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transmission of an escape mutant, may nonetheless benefit from the fact that some of 
these mutants reduce viral replicative capacity. 
 
One further point to note in comparison of maternal viral sequences from samples taken 
as close to the time of transmission as possible (a median of 2-3 weeks prior to 
delivery) and child sequences, also taken as close to the time of transmission as 
possible (at a median of 31 days age), is the lack of identity between early child 
sequences and maternal sequences when variants are involved. Focusing on the 4 Gag 
epitopes highlighted in this study, and sequences in the 16 mother-child pairs where 
mother and/or child possesses one of the protective HLA-B alleles (Table 3.2) variants 
are seen in mother or child sequences in 24 of 64 epitopes. However, the variants differ 
between mother and child in as many as 9/24 instances. In some cases this may be due 
to the fact that sequences were not determined from viral RNA, but from proviral DNA. 
However, another possibility is that the most frequent variant present in the mother is 
not necessarily the variant most likely to be transmitted, a finding previously well 
described in relation to MTCT (Wolinsky et al., 1996). Finally, it is possible that very 
early escape may be selected in the infant, even in utero. In the case of 562-C/M, for 
example, the mother did not have an HLA allele driving variant selection at Gag-146, 
and only wild-type Gag sequences were observed. The child had HLA-B*5801, 
however, and at day 1 of life, the child has virus encoding the B*5801 Gag mutant 
A146P, and no response to the epitope ISPRTLNAW was detected. In contrast, a strong 
response was initially observed to the B*5801 epitope TSTLQEQIAW; the escape 
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mutant in this epitope, T242N, was only first noted at 10 months of age, coincident 
with a decline in the size of the CD8+ T-cell response (Fig 3.2).  
 
Taken together, these data suggest that infected children have the potential to generate 
Gag-specific CD8+ T-cell responses and delay disease progression if they possess 
protective HLA-B alleles to which the transmitted maternal virus is not pre-adapted.  
As in adult infection, the protective HLA class I alleles that drive selection of Gag 
escape mutations are not only beneficial to the infected mother, but also to the infected 
child not expressing the same alleles. These studies and those reported before could 
help identify individuals who qualify for delayed treatment as a result of the advantage 
of acquisition of a less fit virus. This may be especially relevant to infected children, 
since the generally observed rapid progression observed in infancy currently dictates 










CHAPTER 4 : T CELL ACTIVATION AND 
POLYFUNCTIONALITY PROFILES IN 
PROGRESSIVE AND NON-PROGRESSIVE 




(A sub-section of work described in this chapter has now been published in AIDS 
Research and Human Retroviruses, 2011, Sep Issue. See Appendices section) 
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4.1. INTRODUCTION  
According to UNAIDS, an estimated 370,000 children became newly infected with 
HIV in 2007 (UNAIDS, 2008) and HIV-1-infection is the underlying reason for more 
than one-third of deaths in children younger than 5 years. The majority of these 
infections are through mother-to-child-transmission. In contrast to adults, the natural 
history of HIV-1 disease is very rapid in children, and without antiretroviral treatment 
(ART), more than 50% of HIV-1-infected children will die within the first 2 years of 
life (Brahmbhatt et al., 2006, Newell et al., 2004, Mphatswe et al., 2007). Several 
factors might account for this rapid disease progression in children, including the 
immature neonatal immune system, and the transmission of viruses that have adapted to 
the mother’s HLA class I genotype and include viral escape variants within CTL 
epitopes restricted by those HLA class I alleles shared between mother and child 
(Goulder et al., 2001a, Mphatswe et al., 2007, Thobakgale et al., 2009). However, a 
small proportion of children are able to control the virus for years without the need of 
ART. The correlates of this delayed disease progression in children are not understood.  
 
Superior control of HIV-1 replication in long-term non-progressors has been associated 
with CD8+ T cells that express multiple effector functions upon recognition of cognate 
antigen (Almeida et al., 2007, Betts et al., 2006, Seder et al., 2008). However, the 
generalised T cell activation that characterises HIV-1 infection has been suggested to 
lead to accelerated proliferation, expansion and death of CD4+ and CD8+ T cells 
(Grossman et al., 2002, Kovacs et al., 2001). Continuous stimulation of T cells in HIV-
1 infection can also result in functional impairment, senescence and activation-induced 
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deletion of HIV-1-specific CD8+ T cell clones (Brenchley et al., 2003, Lichterfeld et 
al., 2004a, Palmer et al., 2005, Streeck et al., 2008). Furthermore, the level of HIV-1-
induced immune activation has been strongly associated with the speed of HIV-1 
disease progression in adults. In contrast, the consequences of HIV-1 infection on T 
cell functions are much less understood in paediatric HIV-1 infection, but several 
studies suggest an important role of virus-specific CD8+ T cells (Feeney et al., 2005, 
Feeney et al., 2004, Leslie et al., 2004, Thobakgale et al., 2009, Huang et al., 2008) and 
T cell activation (McCloskey et al., 2001, Paul et al., 2005, Sherman et al., 2002) in the 
control of paediatric infection.   
 
Here, we analyzed T cell activation and function in HIV-1 infected children with rapid 
and slow disease progression over the first 3-4yrs of life, using samples from a 
previously described paediatric cohort (Thobakgale et al., 2009, Thobakgale et al., 
2007). We observed that children with delayed disease progression had lower levels of 
T cell activation and senescence and more polyfunctional HIV-1-specific CD8+ T cells 
than children with rapid disease progression. These studies suggest that the quality of 
the antiviral CD8+ T cell response can make an important contribution to outcome in 






4.2. MATERIALS AND METHODS  
4.2.1. Study Subjects 
Fifteen perinatally HIV-1-infected infants were longitudinally studied from birth. This 
paediatric study cohort including exclusion and inclusion criteria has been previously 
described (Mphatswe et al., 2007, Prendergast et al., 2008, Thobakgale et al., 2009, 
Thobakgale et al., 2007). Briefly, we enrolled HIV-1-infected infants born to HIV-1-
infected mothers at St Mary’s and Prince Mshiyeni hospitals in Durban, South Africa 
between 2003 and 2005. The HIV-1 seropositive mothers were recruited in the last 
trimester of pregnancy. The study was approved by the Ethics Committee of University 
of KwaZulu-Natal. The mothers gave written informed consent for participation of their 
children in the study. The mothers and children received single-dose nevirapine at the 
onset of labour and within 48 hours of birth, respectively, according to the HIVNET 
012 protocol (Guay et al., 1999, Jackson et al., 2003).  
 
Study participants were subsequently enrolled into a clinical study, as described 
previously (Mphatswe et al., 2007) and were either followed longitudinally prior to 
initiation of deferred ART (arm A), or received one year of ART following diagnosis at 
birth (arm B). All infants enrolled onto the study received long-term ART once World 
Health Organization (WHO) clinical and/or immunological criteria for antiretroviral 
treatment were met (http://www.who.int/hiv/pub/guidelines/WHOpaediatric.pdf). 
Taking into account that 85% of HIV-1 infected children progressed to CD4 <20% by 1 
year in the absence of ART (Mphatswe et al., 2007), we defined rapid progressors as 
children who met WHO criteria to receive ART within 12 months of birth or within 12 
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months of ART cessation, and slow progressors as children not meeting WHO criteria 
to receive ART for > 36 months. Since progression was rapid in the absence of ART in 
the majority of these children, we here analyzed the remaining 7 children who did not 
require ART after 36 months (slow progressors) and comparison was made with 8 
children who progressed rapidly to disease by 12 months in the absence of ART (rapid 
progressors). The peripheral blood mononuclear cell (PBMC) samples from the fifteen 
individuals were assayed at 3 time points for T cell activation, senescence and 
polyfunctionality: early (median of 4 months, range 2-6 months), intermediate (median 
of 16 months, range 13-23 months) and late (median of 38 months, range 25-55 
months). Clinical characteristics of the study participants are shown in Table 4.1.  
 
4.2.2. Viral Load and CD4 Measurement 
Plasma viral loads were measured using the Roche Amplicor Monitor assay (version 
1.5) and CD4 counts were determined from fresh whole blood using Tru-Count 
technology as previously described (Thobakgale et al., 2007).  
 
4.2.3. HLA Typing 
DNA for HLA typing was done by DNA PCR using sequence-specific primers as 




4.2.4. IFN-γ ELISPOT Assays using Synthetic HIV-1 Peptides 
Ex vivo measurement of T-cells for IFN-γ production was undertaken using an IFN-γ 
ELISPOT assay as previously reported (Kiepiela et al., 2004, Thobakgale et al., 2009, 
Thobakgale et al., 2007). A panel of 410 overlapping peptides (18mers with a 10 
amino-acid overlap) spanning the entire HIV-1 clade C consensus sequence and 
defined optimal peptides matching CD8+ T cell epitopes described for the HLA of the 
patients were used in the ELISPOT assays.  
 
4.2.5. Assessment of T cell activation by multicolor flow cytometry 
Ex vivo measurement of T cells for expression of the activation marker CD38 and 
senescence marker CD57 were performed. In brief, freshly thawed cryopreserved 
PBMCs were resuspended to 1-2 x 106 cells/ml in R10 media (RPMI 1640 
supplemented with 10% heat-inactivated FCS), 100 U/ml penicillin, 1.7mM sodium 
glutamate, 5.5ml HEPES buffer) and rested for 2 hours at 370C; 5% CO2. Cells were 
then adjusted to 1x106 cells/ml, washed with PBS (2% PBS/FCS), stained for 
intracellular amine groups to differentiate between live/dead (violet viability dye 
(Invitrogen) and incubated for 30 min at 40C. Following incubation, cells were washed 
and stained with the following surface antibodies: anti-CD19 Pacific Blue (Caltag), 
anti-CD3-PE Cy5.5 (Caltag), CD4-Alexa 700, CD8-APC Cy7, CD57-FITC and CD38-
PE Cy7 (all from BD Biosciences),  and incubated for 20 min in the dark at room 
temperature.  Cells were again washed and fixed in 1% parafomaldehyde (Fix Perm A, 
Caltag) for 20 min in the dark at room temperature. Following incubation, cells were 
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washed twice with PBS and resuspended in 200µl of PBS before acquisition on LSRII 
flow cytometer (BD Biosciences). 
 
4.2.6. Assessment of T cell functionality by multicolor flow cytometry 
PBMCs were stimulated with peptides corresponding to described optimal CD8+ T cell 
epitopes that represented immunodominant responses in the study subjects (see Table 
4.2; Fig 4.4). T cell functionality was assessed by staining for 4 functions using the 
following antibody panel: anti-CD3-PE Cy5.5 (Caltag), anti-CD4-APC, anti-CD8-APC 
Cy7, anti-IFN-γ-PE CY7, anti-TNF α-Alexa 700, anti-MIP-1β-PE, anti-CD107a-PE 
Cy5 (all from BD Biosciences) as described previously (Streeck et al., 2008). Negative 
control tube with PBMCs alone and positive control containing PBMCs stimulated with 
phorbol myristate acetate (PMA) and ionomycin were included in the assays. The cells 
were then washed twice with PBS and resuspended in 200µl of PBS before acquisition 
on LSRII.  
 
For both activation and polyfunctionality panels, between 500,000 and 1000,000 events 
were acquired per sample and data analysis was performed using FlowJo version 8.8.2 
(TreeStar, Inc.). Initial gating was on CD3 versus time to eliminate random laser 
events, followed by removal of doublets by forward scatter height (FSC-H) versus area 
(FSC-A). Live/dead and B cells were discriminated by the use of viability dye and 
CD19 in the Pacific Blue channel respectively; subsequently lymphocyte population 
was gated on, followed by identification of CD8+ and CD4+ T cells. For functional 
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analysis, gates for each of the measured four CD8+ T cell functions (IFN-γ, TNF-α, 
MIP-1β, CD107a) were set based on the negative control (unstimulated, media only).  
 
Boolean gating was used to create a full array of the 16 possible response patterns when 
testing four functions. Data reported here are after background subtraction and were 
further analysed using SPICE 5 and PESTLE software programmes (provided by Mario 
Roederer and Joshua Nozzi, NIAID, NIH). For the activation panel, gates were set as 
indicated above for polyfunctionality panel until CD4+ and CD8+ populations were 
identified. The respective gates for percentage of CD57+ cells and median fluorescence 
intensity (MFI) for CD38+ cells were set based on fluorescence minus one (FMO) 
control tubes for the respective markers.  
 
4.2.7. Statistical Analysis 
Statistical analyses and graphs were plotted on Graphpad prism (version 5). Mann-
Whitney test was used to compare differences between the medians in the expression of 
CD38, CD57 and IFN-γ by T cells between slow and rapid progressor children. The 
same test was also used to compare differences between the medians in proportions of 
CD8+ T cells expressing multiple functions. The Spearman rank correlation test was 
used to determine correlation between T cell activation and senescence on viral load 
and duration of infection. SAS version 9.1.3 (SAS Institute Inc., Cary, NC) was also 
used for analysis. Multiple regression analysis was performed using linear mixed 
models, taking into account longitudinal measurements, for viral load, CD38 MFI, 
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CD57, age and effects of ART. In this analysis, log transformation was applied to viral 




4.3.1. Longitudinal measurement of T cell activation and senescence in slow-
progressor and rapid-progressor children 
Nine of the 15 enrolled infants described here received short-term ART in the first 12 
months of life as part of the primary clinical study; the remaining infants did not 
receive immediate ART upon diagnosis (Mphatswe et al., 2007). Children were 
assigned into 1 of 4 groups (Table 4.1), on the basis of whether they were randomized 
into early ART or not and whether or not they remained off ART for >36 months. 
 
T cell activation has been described as a better predictor of disease progression than 
viral load in adult and paediatric infection (Deeks et al., 2004, Giorgi et al., 1993, 
Sherman et al., 2002, Paul et al., 2005). We investigated CD4+ and CD8+ T cell 
activation levels by measuring CD38 expression in slow and rapid progressor children 
in the first 3-4 years of life before and after ART. In the arm A group (deferred ART), 
rapid progressors showed higher levels of CD8+ T cell activation at the early time-
point, which decreased at the intermediate and late time-points subsequent to ART (Fig 






















cell activation than rapid progressors, and these levels of activation declined but did not 
change significantly over time (Fig 4.1A). Similar trends were noted for CD4+ T cell 
activation, with the exception that slow progressors showed higher levels of activation 
than rapid progressors at the early time point. The immediate treatment group (arm B) 
had lower CD8+ T cell activation during early infection compared to untreated (arm A) 
infants. Activation increased in rapid progressors when treatment was interrupted and 
later decreased when treatment was resumed; in contrast, slow progressors maintained 
Participants HLA-Type Early Intermediate Late
Age (mo) VL a CD4% Age (mo) VL CD4% Age (mo) VL CD4%
Arm A (n=6)
Slow-Progressors
A-517C A3002/6802 B1510/4201 Cw03/1701 4mo 5,620,000 25 18mo >750000 27 48mo 40,535 36
A-133C A6801/7408 B5802/8101 Cw04/0602 6mo 180,000 38 16mo 40,600 32 55mo 18,300 32
Rapid-Progressors
A-298C A29/6802 B13/1401 Cw06/08 6mo 318,000 11 14mo 1,050 17 33mo <50 23
A-562C A0205/3002 B1402/5801 Cw07/0802 6mo 11,860 10 13mo 519 29 27mo <50 27
A-458C A4301/6802 B1503/1510 Cw03/18 3mo 583,000 17 20mo <50 43 29mo <50 48
A-447C A03/6802 B1401/4701 Cw0602/0802 2mo 7,820,000 25 20mo 717 33 25mo <50 34
Arm B (n=9)
Slow-Progressors
B-114C A0301/24  B07/08  Cw07/07 N/Ab N/A N/A 23mo 249,000 24 46mo 11,800 19
B-380C A2301/6802 B1510/1510  Cw03/08 5mo 101 40 20mo 65,200 31 38mo 373,000 30
B-559C A2301/6802  B0801/5801  Cw07/07 4mo <50 53 21mo 973,000 25 38mo 356,000 21
B-586C A0101/6802 B1510/8101 Cw08/1801 2mo 387 38 15mo 137,000 30 42mo >750000 18
B-021C A0205/29 B4201/44 Cw0202/1701 5mo <50 33 16mo >750000 33 38mo 99,895 24
Rapid-Progressors
B-001C A0101/3001 B4201/8101 Cw17/1801 4mo <50 54 21mo 236,000 25 47mo <50 29
B-222C A29/6802 B0702/1302 Cw0602/07 N/A N/A N/A 13mo 56,900 11 N/A N/A NA
B-675C A6601/6802 B1510/39 Cw03/12 4mo 1,290 47 16mo 714,000 14 37mo <50 37
B-732C A3002/6602 B4201/45 Cw1601/1701 3mo 2,000 22 15mo 654,000 17 N/A N/A NA
a-plasma HIV RNA measurement; dilutions for quantification of high VL >750000 was done for some and not all patients due to inadequate sample availability
b-N/A-sample not available for measurement
Shaded grey area indicates time on ART, applicable to Arm A rapid-progressor children at the intermediate and late time-points; all Arm B children
at the early time-point and Arm B rapid-progressors at the late time-point
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stable CD8+ T cell activation levels throughout the measured time-points (Fig 4.1A, 
B). While rapid-progressors had higher levels of CD8+ T cell activation than slow-
progressors within the two groups, which decreased with ART, the differences did not 
reach statistical significance (P=0.19, Mann-Whitney; Fig 4.1A,B). 
 
Chronic stimulation with HIV-1 can result in proliferation-incompetent T cells which 
may lead to failure of the T cells to effectively suppress viral replication (Bestilny et 
al., 2000). Concurrent with activation measurement, we also monitored T cell 
senescence by measuring CD57 expression on CD8+ and CD4+ T cells at the 3 
described time points (Table 4.1). In both the immediate and delayed treated groups, 
there was a trend towards more elevated CD57 expression levels in rapid-progressors 
than in slow progressors in both CD8+ and CD4+ T cells (Fig 4.1C, D); with a few 
exceptions (arm B slow-progressors had more CD57 CD8+ T cell expression). The 
expression of CD57 increased from early to late infection in slow-progressors in the  
absence of ART. Rapid progressors had higher levels of CD57 expression in the 
absence of ART; however, these decreased on CD4+T cells when ART was resumed 
(Fig 4.1C, D) and there was minimal change of CD57 expression on CD8+ T cells. 
These changes in CD57 expression over time were not significantly different between 
slow and rapid progressors. CD4+ T cells displayed much lower levels of CD57 than 
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Figure 4.1. T cell activation profiles in slow-progressor (SP) and rapid-progressor (RP) 
children at different stages of HIV-1 infection.  Assessment of CD38 (A, B) and CD57 (C, 
D) expression on CD8+ and CD4+ T cells in arm A (left panels) and arm B (right panels) 
children. Dot plots shows medians and shaded area in grey indicate time on ART. 
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In agreement with previous studies (Deeks et al., 2004, Sherman et al., 2002), the CD38 
MFI significantly correlated positively with viral load on CD8+ T cells (P=0.036, 
Linear mixed model; Fig 4.2A) and on CD4+ T cells (P=0.027, linear mixed model; Fig 
4.2B) in children through the course of infection. Furthermore, the expression of CD57 
significantly correlated positively with age for CD8+ T cells (P=0.006, linear mixed 
model; Fig 4.2D) but not for CD4+ T cells (P=0.07, linear mixed model, Fig 4.2D). In 
addition, there was a significant negative correlation between viral load and the 
frequency of CD57 positive CD8+ (P=0.028, linear mixed model; data not shown) but 
did not reach significance on CD4+ T cells (P=0.17, linear mixed model; data not 
shown). Together these data show that high viral load levels induce T cell activation 
and senescence from early through to chronic infection, and that these T cell 
phenotypes are antigen driven as the expression of these markers is affected by ART. 
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Figure 4.2. Correlation of CD38 and CD57 expression on T cells with viral load and 
period of infection in children. The graph show the correlations between Median 
Fluorescence Intensity (MFI) of CD38 on CD8+ (A) and CD4+ (B) T cells, respectively, 
and viral loads, and the correlations between the percentage of CD8+ (C) and CD4+ (D) T 
cells expressing CD57 and age (in months) in all participants plotted for all time-points 
studied (as detailed in Table 4.1). 
 
4.3.2. Evaluation of dominant CD8+ epitopes for IFN-γ production by ELISPOT 
and ICS assays 
We previously reported in this same cohort of children that the majority of in utero-
infected infants mount CD8+ T cell responses in the first days of life (Thobakgale et 
al., 2007); however, disease progression is still rapid in most untreated HIV-1-infected 
children (Mphatswe et al., 2007). We first monitored the persistence of HIV-1-specific 
T cell responses over the first 3-4yrs post infection using the IFN-γ ELISPOT assay in 
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the fifteen slow-progressor and rapid-progressor children, and confirmed 
immunodominant responses by flow cytometry using ICS (Table 4.2). IFN-γ+ CD8+ T 
cell responses (gated as shown in Fig 4.3), increased over the course of infection in 
untreated children, and decreased following initiation of ART. However, no significant 
differences in the studied IFNγ+ CD8+ T cell responses were noted between slow-
progressor and rapid-progressor children (Fig 4.4).  
 
Untreated children (all arm A) had significantly higher IFN-γ producing CD8+ T cells 
than the children who received immediate ART upon diagnosis (all arm B) at the early 
time-point, (median 0.16% vs 0.00%;  P=0.036; Mann-Whitney, data not shown); and 
there was a significant increase in the responses in arm B children when treatment was 
stopped at the intermediate time-point (median 0.0% vs 0.7%; P<0.0001, Mann-
Whitney, data not shown), resulting in higher HIV-1-specific IFN-γ+ CD8+ T cell 
responses in children in arm B who discontinued ART compared to those in the 
untreated group (median 0.16% vs 0.7%; P=0.024, Mann-Whitney, data not shown). 
Taken together, these data demonstrate dynamic changes in the frequency of IFN-γ+ 
HIV-1-specific CD8+ T cell frequencies in response to HIV-1 replication, but the 


















Figure 4.3. Measurement of HIV-1-specific CD8+ T cell functionality by multicolor 
staining in slow-progressor and rapid-progressor children Representative gating scheme 
for identification of polyfunctional HIV-1-specific CD8+ T cells following stimulation with 
HIV-1 peptide is shown for one individual. Initial gating was on the CD3 versus time to 
eliminate random laser events, followed by removal of doublets by forward scatter height 
(FSC-H) versus area (FSC-A). Live/dead and B cells were discriminated by the use of 
viability dye and anti-CD19 respectively versus CD3; subsequently lymphocyte 
population was gated on followed by identification of CD8+ and CD4+ T cells. Gates for 
each of the measured four CD8+ T cell functions were set based on the negative control 
(unstimulated, media only). Boolean gating was used to create a full array of the 16 
possible response patterns when testing four functions.  
98 
 
Table 4.2. Intracellular IFN-γ measurement of CD8+ T cell in responses to dominant 
















Participants Optimal Epitope Epitope Sequence Early Intermediate Late
Arm A (n=6) % IFN-γ+ CD8+ T Cells
A-517C B42-TL9 (Gag) TPQDLNTML 0.00 0.33 0.11
CW3-YL9 (Gag) YVDRFFKTL 0.16 0.00 0.00
A-133C B81-TL9 (Gag) TPQDLNTML 0.08 0.37 1.05
A-298-C A29-SY9 (Env) SFDPIPIHY 0.45 0.00 0.04
A29-RW10 (Gag) RQANFLGKIW 0.02 0.00 0.12
A-562C B58-TW10 (Gag) TSTLQEQIAW 0.16 0.06 0.07
A-458C CW3-YL9 (Gag) YVDRFFKTL 0.36 0.11 0.00
A-447C CW8-TL9 (Gag) TPQDLNTML 0.86 0.11 0.00
Arm B (n=9) 
B-114C CW7-KY11 (Nef) KRQEILDLWVY ND 0.16 2.35
A23-RW8 (Nef) RYPLTFGW ND 0.32 0.26
B-380C B1510-GL9 (Gag) GHQAAMQML 0.00 0.46 1.70
B1510-VL10 (Gag) VHQAISPRTL 0.00 0.13 0.20
A23-RW8 (Nef) RYPLTFGW 0.00 0.22 0.96
B-559C B58-TW10 (Gag) TSTLQEQIAW 0.10 0.12 0.40
CW7-KY11 (Nef) KRQEILDLWVY 0.00 3.10 0.96
B58-KW11 (Env) KAYETEVHNVW 0.14 1.56 0.25
B58-KAF9 (Nef) KAAFDLSFF 0.42 0.81 ND
B-586C B81-TL9 (Gag) TPQDLNTML 0.05 0.64 0.52
B-021C A2-YI9 (Pol) YTAFTIPSI 0.06 2.18 0.08
A29-SY9 (Env) SFDPIPIHY 0.28 1.93 0.16
B42-TL9 (Gag) TPQDLNTML 0.00 0.39 0.74
B-001C B81-TL9 (Gag) TPQDLNTML 0.00 3.17 0.47
B-222C B7-TL10 (Nef) TPGPGVRYPL ND 0.12 ND
B-675C CW3-YL9 (Gag) YVDRFFKTL 0.09 3.42 0.19
B-732C B45-GV11 (Nef) GEVGFPVRPQV 0.00 0.73 ND















































Figure 4.4. Longitudinal intracellular measurement of IFN-γ expression by CD8+ T cells. 
Measurement of CD8+ IFN-γ+ CD8+ T cells by ICS in arm A (top panel) and arm B 
(bottom panel) slow (SP) and rapid-progressor (RP) children throughout the first 3-4 
years of life. Dot plots shows median values of the different epitopes (as shown in Table 




4.3.3. Polyfunctionality of CD8+ T cell responses in slow and rapid progressor 
children over the course of infection 
Since IFN-γ expression alone could not discriminate disease outcome in this cohort of 
HIV-1-infected children, we next evaluated T cell polyfunctionality (as represented in 
Fig 4.3); defined as the ability of HIV-1-specific-CD8+ T cells to produce multiple 
cytokines and chemokines in response to viral antigen. HIV-1-specific CD8+ T cell 
polyfunctionality has previously been associated with viral control in adults (Betts et 
al., 2006). Slow progressors in the delayed treatment group displayed more 
polyfunctional (4 functions) CD8+ T cells in the first 6 months of life than rapid 
progressors, which increased at the intermediate time point and decreased at the last 
time point. Rapid progressors in the same group had less polyfunctional HIV-1-specific 
CD8+ T cells than slow progressors, which decreased with disease progression and did 
not improve with ART at the intermediate and late time-points (Fig 4.5A).  
 
Slow-progressors in the immediate treated group had more monofuntional to 3 
function-expressing T cells at the early time-point while on ART, and only gained more 
functions (up to 4 functions) when viral load increased at the intermediate time point, 
subsequently decreasing with disease progression at the late time point. The proportion 
of ≤3 functions did not differ between slow and rapid progressors in the immediate 
treated group; however, CD8+ T cells expressing 4 functions were lower at the early 
and intermediate time point and increased at the late time-point when ART was 
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Figure 4.5.(A-B) Representative functional composition of CD8+ T cell responses in slow-
progressor and rapid-progressor children. The functional flavour of the individual 
response patterns to IFN-γ, Mip-1β, CD107a, and TNF-α is denoted by coloured dots; red 
(early), yellow (intermediate), green (late time-points) for arm A (A) and arm B (B) 
children. The proportion contributed by the response pattern from slow-progressor (top 
panel) and rapid-progressor (bottom panel) individuals, and the inter-quartile ranges are 
shown. The response patterns for each individual and the epitopes studied (as depicted in 
Table 4.2) were grouped and colour-coded by the number of functions and summarized in 
pie chart form where each slice of the pie represents the fraction of the total epitope-
specific response that consist of CD8+ T cells with the respective number of functions. 
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Next, we evaluated if the proportion of CD8+ T cells expressing all 4 functions could 
predict disease outcome in these children (Fig 4.6). Slow progressors were analyzed by 
combining arm A (early time point) and arm B (immediate time point) groups when off 
ART and determining the proportions of HIV-1-specific CD8+ T cells expressing 
different number of functions; a similar analysis was undertaken on rapid progressors. 
No significant differences were noted for 1, 2, and 3 functions (≤3 functions) between 
slow and rapid progressor children; however, there were more polyfunctional (4 
functions) HIV-1-specific CD8+ T cells in slow progressors than in rapid progressors 
(P=0.05, Mann-Whitney; Fig 4.6). Taken together these data suggest that with 
continuous viral stimulation in the absence of ART, polyfunctionality of HIV-1-








































Figure 4.6. Summarized comparison of the overall proportions of polyfunctional CD8+ T 
cells in slow-progressor and rapid-progressor children. Top panel Polyfunctionality as 
depicted on the pie charts was obtained by grouping slow-progressors (left pie chart) and 
rapid-progressors (right pie chart) at comparable time-points while not on ART. For arm 
A this was the early time-point (slow progressors, n of individuals=2, n of epitopes=3; 
rapid progressors, n of individuals=4, n of epitopes=5) and for arm B this was the 
intermediate time-point (slow progressors, n of individuals=4, n of epitopes=13; rapid 
progressors, n of individuals=4, n of epitopes= 5). The pie charts represent the medians of 
the different functions for the two groups at the stipulated time points. Bottom panel The 
contribution of HIV-1-specific CD8+ T cells with 4 functions to the overall virus-specific 
CD8+ T cell response was compared between the combined slow (n of individuals=7, n of 




A small group of perinatally HIV-1 infected children maintain immunological control 
and display slow disease progression. Multiple factors may contribute to delayed HIV-1 
disease progression in adults, however very little is known about these factors in 
paediatric infection. Here we assessed T cell activation and function in the slow 
progressor children compared to rapid progressors, and we observed variable levels of 
T cell activation and T cell senescence that did not differ significantly between slow 
and rapid progressors. We also noted low levels of polyfunctional CD8+ T cells in 
rapid compared to slow progressors. The expression of CD38 on CD8+ T cells 
correlated positively with viral load while CD57 expression levels on T cells increased 
with age and correlated negatively with viral load, supporting earlier findings that 
continued T cell activation leads to T cell dysfunction. These data show that differences 
in T cell phenotypes as a consequence of immune activation may exist in slow and 
rapid progressor children.  
 
Previous studies in adults have found a strong relationship between the level of 
viraemia and the levels of both CD4+ and CD8+ T cell activation (Deeks et al., 2004). 
It has also been demonstrated that persistent viral stimulation gradually drives CD4+ 
and CD8+ T cells to lose their replicative capacity and become senescent; such loss of 
high quality T cells may play a role in the onset of disease progression (Appay et al., 
2007). In line with this, our findings show a strong correlation in the level of CD8+ and 
CD4+ T cell activation and viraemia and also show a significant increase in CD8+ T 
cell exhaustion from acute to chronic paediatric infection but not on CD4+ T cells. The 
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CD38 expression levels were higher in rapid progressors than in slow progressors and 
as expected decreased with the introduction of ART, thus confirming that high 
expression of this parameter is associated with high viral load levels. It was unexpected 
to note a negative correlation between CD57 expression on CD8+T cells and viral load 
given that exhaustion of HIV-specific CD8+ T cells is driven by antigen stimulation. It 
is possible that continual viral stimulation results in generation of HIV-specific T cells 
that express high levels of CD57 that are prone to apoptosis as previously proposed 
(Brenchley et al., 2003), thus masking a positive correlation at a steady state.  
A negative correlation between CD57 expression by CD8+ or CD4+ T cells and viral 
load as previously been noted by others (Lieberman et al., 1999) may be indicative of  
antiviral activity of cells bearing this phenotype (Landay et al., 1993, Roederer et al., 
1997).  
 
In our study, an additional factor reflecting differences between slow and rapid disease 
progression in children was the quality of the HIV-1-specific CD8+ T cell response. 
Expression of IFN-γ alone by virus-specific CD8+ T cells, as has been traditionally 
measured by ELISPOT and ICS assays, was not sufficient to discriminate between slow 
and rapid progressors. We noted that, individuals who received short-term ART (arm 
B) had higher frequencies of IFN-γ+CD8+ T cell responses when treatment was 
interrupted, in comparison to untreated children (arm A). Augmentation of T cell 
responses following interruption of ART has been well documented (Ortiz et al., 2001, 
Papasavvas et al., 2000). However, it cannot be ruled out that qualitative differences 
exist in the T cell responses generated by these children. This may in part account for 
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the rapid progression to disease observed in majority of infected children despite early 
detection of IFN-γ+ CD8+ T cell responses in the first months of life (Lohman et al., 
2005, Thobakgale et al., 2007).  
 
Indeed, differences were observed when more CD8+ T cell functions in response to 
antigen were measured by multiparameter flow assays; HIV-1-specific CD8+ T cell 
responses in slow progressors displayed a higher proportion of polyfunctional T cell 
responses than rapid progressors. Notably, these responses were different at the earliest 
time-point off ART when viral loads were not yet different between the two groups. 
This finding is consistent with previous observations in studies of adult long-term-non-
progressors who displayed polyfunctional HIV-1-specific CD8+ T cells (Betts et al., 
2006). An alternative explanation for this result may be that slow progressors had more 
antigen specific CD8+ T cells than rapid progressors as the number of epitopes targeted 
by individuals between the two groups was variable. Here, we detected polyfunctional 
HIV-1-specific CD8+ T cell responses in children younger than 6 months of age. In 
contrast, in a recent study, polyfunctional responses were less common in children 
younger than 24 months and hardly detected in children less than 12 months (Huang et 
al., 2008). A possible explanation for these differences could be viral subtype or host 
genetic differences, timing of infection as most infants in our cohort were infected in-
utero, and also that peptides corresponding to optimal CD8+ T cell epitopes and not 




The heterogeneity of the cohort studied here in terms of ART, and the limited number 
of patients did not allow us to establish a clear-cut relationship between polyfunctional 
HIV-1-specific CD8+ T cell responses and viral load, their maintenance over the time 
of infection, and changes in responses on ART. In addition, CD38 alone rather than 
CD38 and HLA-DR, was determined as a measure of T cell activation. A recent study 
examined both markers of activation on CD4+ and CD8+ T cells in Ugandan children 
with age ranges of 1-10 years, found a correlation with CD4 T cell counts but not with 
viral load (Ssewanyana et al., 2007). An additional limitation in our study is that the 
heterogeneity of slow and rapid progression noted here may have been confounded by 
antiretroviral treatment with some receiving deferred treatment (n=6) while the rest 
(n=9) were initiated on treatment at the time of diagnosis and then discontinued after 
one year. Therefore our observations need to be interpreted cautiously as they may not 
be generalized to the natural course of disease in the absence of antiretroviral therapy. 
In previous studies, the presence of 3 or more functions depicts polyfunctionality and is 
associated with slow disease progression. In our analysis, the effect of polyfunctionality 
as assessed by 3 functions did not differ between slow and rapid progressors but was 
only seen with regards to 4 functions. Follow-up studies to address these questions in a 
homogeneous cohort with large numbers of therapy-naïve children are warranted. 
However, these may be difficult to undertake in future since the high risk of rapid 
progression in children requires immediate ART intervention following diagnosis 
(Mphatswe et al., 2007, Violari et al., 2008) that is now provided to all HIV-1-infected 




To our knowledge, this is the first study to simultaneously assess T cell 
polyfunctionality, activation and senescence from early through to chronic HIV-1 
infection in a cohort of slow and rapid progressor children. We conclude that rapid 
progression in paediatric infection is associated with early immune activation which 
can drive T cells to gradual functional exhaustion. In addition, we show that the quality 
of the HIV-1-specific CD8+ T cell response is associated with immunological outcome 
in paediatric HIV-1 infection as has previously been shown for adult infection. The 
introduction of early ART in infants following diagnosis as currently recommended, 
will overlook the few children likely to be able to spontaneously control replication of 
the virus.  However, early initiation of ART will preserve T cell functionality in the 
majority of rapid progressor children and is clearly justified given the difficulty in 
discriminating between these two groups during routine clinical care. The potential to 
discontinue early ART following the initial period of rapid disease progression in 
children is currently under investigation (Violari et al., 2008). Studies of T cell function 
might help as a laboratory biomarker for guiding the management of HIV-1-infected 










CHAPTER 5 : GENERAL DISCUSSION, FUTURE 











5.1. GENERAL DISCUSSION 
Paediatric HIV-1 infection is characterized by high viral loads that do not decline to 
viral set point until two or more years of life. This failure to control viremia is 
attributed to the delayed development of CD8+ and CD4+ T cell responses during early 
life and may thus contribute to the rapid disease progression noted in infants in the 
absence of antiretroviral therapy (ART). We examined a cohort of infants infected 
either during pregnancy (in-utero) or at birth during delivery (intrapartum) and we 
show that CD8+ T cell responses were detected in the first days of life in in-utero 
infected children and within the first months in infants infected intrapartum. Env and 
Rev were the most frequently targeted proteins during early infection compared to Gag, 
Pol and Nef that were dominantly targeted by chronically infected children (chapter 2).  
 
The sharing of protective HLA alleles between mother and child influenced disease 
outcome in the child as a result of inability of the child to generate CD8+ T cell 
responses following adaptation of the transmitted virus in the mother and also brought 
benefit to the child as a consequence of acquisition of less fit viruses from the mother 
(chapter 3). The quality of the T cell response as assessed by simultaneous 
measurement of T cell polyfunctionality, activation and senescence determined slow 
and rapid progression to disease in children over time in the absence of ART (chapter 
4). 
 
These key findings are discussed in detail in the sections below, with particular 




5.1.1. Timing, specificity and polyfunctionality of the CD8+ T cell response and 
disease progression in paediatric HIV-1 infection 
The lack of viral load decline in children in the first years of life is a key distinguishing 
factor of paediatric when compared to adult HIV infection. In adults, acute infection is 
marked by high viral loads, the emergence of T cell responses and subsequent decline 
to viral set point within weeks of infection. The timing of T cell response development 
and its effect in slowing disease progression following vertical transmission remains 
controversial (Buseyne et al., 1998, Lohman et al., 2005, Luzuriaga et al., 1995, 
Luzuriaga et al., 1991, McFarland et al., 1994, Wasik et al., 1997). Prior studies in 
infants were limited by cell availability, small sample size and less comprehensive 
assays without defined timing of infection. 
 
In this analysis of 63 HIV infected children, we set out to understand some of the 
factors that mediate pathogenesis in paediatric infection. We defined in-utero and 
intrapartum infections and systematically determined the age at which CD8+ T cell 
responses are generated and the specificity of the responses using peptides spanning the 
whole HIV genome. CD8+ T cell responses were detected as early as the first week of 
life in 70% of in-utero infected infants and after a month in intrapartum infected infants 
(Thobakgale et al., 2007). Our findings support previous suggestions by others that the 
capacity to generate CD8+ T cell responses may start from early foetal life (Luzuriaga 
et al., 1995, Marchant et al., 2003, Vermijlen et al., 2010), thus suggesting that 
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perinatal HIV vaccination of infants is feasible because they have the ability to mount 
immune responses in response to viral antigens.  
 
The differences in the specificity of the response targeted towards Env and Rev in acute 
paediatric infection and towards Gag, Pol and Nef in chronic paediatric infection may 
have important vaccine implications following reports in adults that Gag responses are 
associated with low viral load and Env responses with high viral loads (Kiepiela et al., 
2007). This may be the case for paediatrics as well since a recent study in infants found 
an inverse correlation between Gag responses and viral load in infants younger than 24 
months (Huang et al., 2008), suggesting that Gag responses may be beneficial in 
neonates. The notable rapid progression to disease in the first year of life in 85% of the 
infants who delayed ART (Mphatswe et al., 2007) despite detection of T cell responses 
immediately after infection may suggest that these early responses are dysfunctional in 
infants. This is in contrast to acute adult infection where the development of CD8+ T 
cell responses coincides with a temporal viral load decline and subsequent viral control 
(Koup et al., 1994).  
 
The long-term benefits of these responses could not be established between in-utero 
and intrapartum infected infants in our cohort as 75% of the infants started ART shortly 
after diagnosis. However, longitudinal follow-up over 12 months in a few infants 
suggested that these responses may have been beneficial in some infants (Thobakgale et 
al., 2007). An earlier study (Lohman et al., 2005), found no differences in peak viral 
load and magnitude of the early responses between in-utero and intrapartum infected 
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infants, indicating a lack of clinical benefit regardless of early detection of responses 
also in infants <12 months. In contrast to our study, many children failed to generate 
responses at the earliest time points measured, it is possible that defined optimal 
epitopes used in that study rather than the entire HIV proteome peptides may have 
accounted for the differences (Lohman et al., 2005). 
 
Consistent with our findings, a recent study in clade C infection also detected CD8+ T 
cell responses at 6-10 weeks of age and at birth in in-utero infected infants. However, 
in contrast Nef was found to be dominantly targeted by most infants (Shalekoff et al., 
2009). The differences in methodologies and the variability in the number of in-utero vs 
intrapartum infants studied between the two studies may explain the differences. Whole 
blood ICS rather than IFN-γ Elispot was used in the study by Shalekoff et al, and in 
addition, 18 infants (6 in-utero, 6 intrapartum and 6 with unknown timing of infection) 
were studied in comparison to 63 infants, (44 in-utero and 19 intrapartum) in our study. 
The majority of in-utero infections in our study were evaluated for T cell responses 
within the first 2 weeks of life, while Shalekoff et al measured T cell responses between 
6-10 weeks in most infants. Thus it is likely possible that there is a temporal shift in the 
T cell specificity in neonatal infection. The long term benefits of these early T cell 
responses was also not demonstrated and it is likely that there was no benefit as no 
significant correlations were observed between the magnitude of the infants’ T cell 




The studies done so far in infants may also highlight that IFN-γ alone as a marker is not 
sufficient for measurement of HIV-specific T cell immunity as it did not predict 
functionality of the CD8+ T cell responses. A possible explanation for the 
ineffectiveness of CD8+ T cell responses seen in infants may be attributed to the 
diminished CD4+ T cell help (Huang et al., 2008, Thobakgale et al., 2007) and the lack 
of CD4 proliferative capacity (Ramduth et al., 2008) during early life, which is in 
contrast to high levels observed in acute adult infection or chronic infected children 
older than 5 years (Feeney et al., 2003, Rosenberg et al., 1997, Zaunders et al., 2004). 
CD4+ T cell help is critical for the maintenance of CD8+ T cell memory, effective 
immunity to chronic viral infections through enhancement of CD8+ T cell effector 
function (Ridge et al., 1998, Zajac et al., 1998). The reasons for CD4+ T cell response 
deficiency during early childhood needs further investigation and it is proposed that it 
may be due to inefficient priming of CD4+ T cells by antigen presenting cells, reduced 
functional capacity or due to suppression by CD4 T regulatory cells (Adkins, 2000, 
Adkins, 2005, Delespesse et al., 1998, Hartigan-O'Connor et al., 2007, Wasik et al., 
2000).  
 
Host factors, timing of transmission and the maternal disease state at the time of 
delivery are some of the factors that can influence disease progression in children 
(Abrams et al., 2003, Dickover et al., 1994, Just et al., 1995). We assessed virological 
and immunological progression of infants infected either in-utero or intrapartum despite 
administration of single dose nevirapine to the mother during labour and to the child 
shortly after birth. As reported by others (Guay et al., 1999), we found that this 
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prevention of mother-to-child-transmission (pMTCT) strategy only managed to reduce 
intrapartum infections and did not have much effect on in-utero infections as 69% 
(44/63) of the infants were infected in-utero compared to 31% (19/63) of intrapartum 
infections.  
 
As expected, the median viral load of the mothers of infected infants were higher than 
the mothers of uninfected infants and the median viral loads of the mothers of 
intrapartum infected infants were higher than those of in-utero infected infants. This 
finding further confirmed reports that the severity of the mother’s disease state may 
have resulted in intrapartum transmission that would have otherwise been avoided by 
single dose nevirapine (Mphatswe et al., 2007). The finding that there was rapid 
progression in the majority of infants studied here, most of which were infected in-
utero, support previous studies that in-utero infected infants progress rapidly to disease 
(Dickover et al., 1998, Kuhn et al., 1999, Mayaux et al., 1996).  
 
Whereas this study enrolled infants between year 2003 and 2005 when single dose 
nevirapine was used for pMTCT and when infants were treated once CD4% declined to 
20%, findings from this study highlighted two key issues in paediatric management. 
First, the urgent need for ART prophylaxis to reduce high viral loads from early 
pregnancy rather than only at labour to reduce both in-utero and intrapartum infections. 
Second, a need for immediate ART intervention in HIV positive infants due to the fast 
progression in the absence of ART. It is encouraging that the current South African 
treatment guidelines as of April 2010, recommends dual antiretroviral therapy in HIV 
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infected pregnant women from 14 weeks of gestation and to the child ART is given 
shortly after birth if confirmed HIV infected (National Department of Health, 2010) 
 
Recent studies suggest that the quality rather than the quantity of the T cell response is 
an important immune correlate of effective control in HIV infection. Individuals who 
maintain low or undetectable viral loads in the absence of ART have proliferative T 
cells that also exhibit multiple effector functions and correlate negatively with viral 
load than individuals with high viral loads (Betts et al., 2006). Most of the studies 
undertaken in children only enumerated T cell responses; however there are limited 
data on the functionality of T cells on disease progression in children. We here 
demonstrated that polyfunctionality may also predict slow disease progression early in 
paediatric infection as shown by the ability of CD8+ T cells to degranulate (CD107a) 
and secrete IFN-γ, TNF-α and MIP-1β.  
 
It is still unknown if polyfunctionality is a cause or effect of viral control. We noted 
differences in slow and rapid progressor children infected as early as the first 6 months 
of life in the absence of ART, when viral loads were not yet different between the two 
groups suggesting that polyfunctionality may lead to viral control (Thobakgale et al., 
2011). However, the limitation of this analysis was the lack of longitudinal assessment 
of this finding due to the introduction of ART at later time points as a result of 
progression to disease in most children studied. While data so far suggest that CD8+ T 
cells may also control viral replication in children, it is possible that other non-CD8+ T 
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cell mechanisms are important in explaining control in children who neither generated 
Gag-mediated CD8+ T cell responses nor expressed protective class I HLA alleles. 
 
5.1.2. HLA in the mother and child and viral replicative capacity on paediatric 
disease progression 
We have shown that T cell responses are mounted shortly after birth and may 
contribute to the long term establishment of viral containment (Thobakgale et al., 
2007). However, in the majority of the infants progression to disease still occured 
despite the presence of CD8+ T cell responses, thus other factors may operate to 
influence disease progression during early paediatric infection. The targeting of Gag 
epitopes by CD8+ T cells mediated by HLA-B alleles is associated with low viral loads 
in adults (Kiepiela et al., 2007), HLA-B alleles known to protect against disease 
progression also drive the selection of Gag-specific escape mutations (Matthews et al., 
2008). However, the mechanisms underlying immune control by protective alleles are 
not well established.  
 
Recent studies in adults have demonstrated that the accumulation of escape mutations 
may reduce fitness and result in lower viral loads benefiting not only the host, but also 
the recipient lacking the protective allele (Chopera et al., 2008, Goepfert et al., 2008). 
However, no benefit was noted in the recipient if the protective alleles are shared with 
the donor as the transmitted virus may have already adapted in the key Gag epitopes 
which are important for mediating control in the recipient (Goepfert et al., 2008, 
Goulder et al., 2001a). Thus the protective effect of the “good” alleles can be exerted in 
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two ways; directly through active CD8+ T cell mediation or through viral attenuation 
from mutations that reduce replication capacity of the virus.  
 
The mother-to-child-transmission model afforded us an opportunity to explore this 
hypothesis in infants for two reasons. First, infants are able to mount Gag specific 
CD8+ T cell responses and induce escape mutations if they have HLA alleles to which 
no maternal adaptation occurred and second, infants also share over half of their HLA 
alleles with the transmitting mothers. We here demonstrate in a cohort of 61 mother-
child pairs that like adults, the expression of protective HLA-B alleles 
(B*5701/B*5703/B*5801/B*81) in infants confers an advantage of slow disease 
progression through the targeting of Gag epitopes presented by these alleles and 
through acquisition of transmitted escape mutations that reduce the replicative capacity 
of the virus. Evidence that these mutations may have rendered the virus less fit was 
demonstrated by the reversion of the mutations in all slow progressor children without 
protective alleles but whose mothers expressed these protective alleles (Thobakgale et 
al., 2009).  
 
The lack of benefit despite acquisition of escape mutations that incurred a cost to viral 
fitness such as the T242N substitution in the B57-restricted TW10 epitope, as was the 
case in one child with rapid disease progression in our study, was related to the 
development of upstream mutations in the cyclophilin A binding loop that restored the 
fitness defect. Indeed this was also noted in another paediatric study showing similar 
analysis that examined 13 mother-child pairs and showed that there was an advantage 
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of the HLA-B57 allele in clade B infected infants born to infected mothers and that 
there was exceptional control of viremia when mutations were within the B57-restricted 
epitopes (Schneidewind et al., 2009).  
 
Consistent with our finding, Schleindenwind et al (2009), found that HLA-B*57 
exerted its protective effect by driving and maintaining a fitness attenuation mutation in 
p24 Gag, interestingly, this benefit was regardless of the parental inheritance. In 
contrast to the latter, a previous study had found that transmission of escape mutations 
within HLA-B27 restricted epitope KK10 resulted in failure to control in children who 
shared these alleles with their mothers and benefited those who inherited the allele 
paternally (Goulder et al., 2001a) as they mounted high frequency responses to the 
KK10 epitope critical for B27 mediated control. Thus, this contrast in the heritability of 
HLA-associated control found in the study by Schleindenwind and others may suggest 
that there may be different mechanisms of protection by the HLA-B*57 and HLA-B*27 
alleles as has been previously demonstrated by the effectiveness of these two alleles at 
different phases of infection (Gao et al., 2005). 
 
Although a limitation to our study was that replication capacity could not be 
demonstrated, we later examined this in a separate study using the same cohort of 
children to further understand whether the biological property of the transmitted virus 
determines slow versus rapid progression in children. We noted differences in 
replicative capacity in slow and rapid progressors in plasma viral isolates obtained as 
early as 4 months of life (Prado et al., 2010). Other factors such as presence of Nef 
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polymorphisms, virus tropism and mutations within the B*57/5801 Gag CD8+ T cell 
epitopes known to influence replicative capacity were also investigated. No major 
differences were noted in viral tropism or presence of Nef polymorphisms between 
slow and rapid progressors (Prado et al., 2010). However, consistent with our study and 
others (Schneidewind et al., 2009, Thobakgale et al., 2009), mutations in Gag epitopes, 
particularly the accumulation of mutations in the B*57/5801 TW10 epitope in the very 
early virus isolates of slow progressors had a lower replicative capacity. The presence 
of upstream compensatory mutations in the cyclophilin A binding loop contributed to 
rapid progression as a result of high replicative capacity (Prado et al., 2010).  
 
This model that the host immune response can have an impact on viral fitness has also 
been demonstrated in explaining non-progression to disease by ‘elite controllers’ versus 
individuals with progressive disease in adult infection (Blankson, 2010). In addition, a 
recent study has suggested mechanistic differences in the impact of escape mutations 
on viral fitness; mutations in Gag p24 were associated with a significant fitness cost 
while mutations in Env did not impact on viral fitness and contributed very little to 
viral control. The authors also showed that the rate of development of escape mutations 
may be associated with the impact on viral fitness; i.e. escape mutations that appear 
slowly may have a greater fitness cost than mutations that emerge rapidly in less 
conserved genes of the virus (Troyer et al., 2009). The latter may explain the 
accelerated disease progression in infants as the immunodominance of Env or Nef 
protein during early paediatric HIV infection could result in rapid emergence of escape 




Taken together these series of studies have demonstrated the importance of Gag 
mediated control in children through active surveillance by CD8+ T cells. These 
responses then drive Gag escape mutations, resulting in virus attenuation through loss 
of replicative capacity, thereby facilitating prolonged viral control. The importance of 
measuring replicative capacity in therapy naïve individuals may be an additional 
indicator together with viral loads and CD4 counts in future monitoring of therapy 
naïve individuals following a recent report in a large adult cohort that suggested that 
measurement of replicative capacity may help predict out how fast or slow individuals 
will progress to disease (Goetz et al., 2010). 
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5.2. Future Directions 
Efforts for the development of a prophylactic vaccine that prevents the establishment of 
chronic HIV infection have so far been unsuccessful or partially effective (Buchbinder 
et al., 2008, Rerks-Ngarm et al., 2009), as a result the focus has also shifted to 
developing a therapeutic vaccine that can boost immune responses and reduce viral 
load while prolonging survival of HIV-infected individuals. To better understand viral, 
immunologic and genetic factors that may provide models for effective HIV 
vaccination, over the past few years research has focused on “elite controllers” who are 
HIV-infected individuals who maintain viral loads <50 copies/ml without antiretroviral 
treatment (Blankson, 2010). Indeed, extensive work in these individuals has brought 
some understanding of the correlates of immune protection in adults; however these 
remain poorly studied in paediatrics. 
 
Attenuation of HIV-specific T cell immunity by the programmed death-1 (PD-1) and 
CTLA-4 pathways has been described in humans and SIV models (Kaufmann and 
Walker, 2009). PD-1 expression levels are high in untreated subjects, correlates with 
viral load and disease progression and decreases on antiretroviral treatment (Day et al., 
2006, D'Souza et al., 2007, Petrovas et al., 2006, Trautmann et al., 2006). Similarly, 
CTLA-4 directly correlates with viral load and indirectly with CD4+ T cell counts but 
unlike PD-1, CTLA-4 is overexpressed on CD4+ T cells and not highly expressed on 
CD8+ T cells (Kaufmann et al., 2007, Zaunders et al., 2006). Blockade of the PD-1 and 
CTLA-4 pathways enhances HIV-specific T cell activity and proliferation. Interleukin-
10 (IL-10) has been identified as a determinant of viral persistence or acute clearance 
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following infection. Inhibition of this pathway by antibody blockade of IL-10 restored 
T cell function and also enhanced viral clearance during chronic lymphocytic 
choriomeningitis viral (LCMV) infection (Brooks et al., 2006, Ejrnaes et al., 2006). 
Simultaneous blockade of IL-10 and PD-1 pathways was found to be effective in 
restoring antiviral T cell responses and also eliminated persistent viral infection, 
suggesting that there may be an advantage of blocking both mechanistically distinct 
pathways (Brooks et al., 2008). These findings may have important therapeutic 
implications as IL-10 expression levels are high in many human chronic viral infections 
such as HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV).  
 
The role of these pathways needs to be elucidated in neonates and such data may help 
explain the CD4+ T cell defect during early childhood and failure of the CD8+ T cell 
responses to resolve viremia in the first few years of life. Limited data so far also 
suggest upregulation of PD-1 in untreated children in comparison to treated and 
uninfected children (Ssewanyana et al., 2009). Regulatory CD4+ T cells (Tregs) 
defined by the expression of the transcription factor FOXP3, maintain a balance in the 
immune system and may be beneficial in HIV infection by suppressing T cell activation 
but may also be detrimental as they might suppress the immune response to HIV 
(O'Connell et al., 2009, Seddiki and Kelleher, 2008). Depletion of Tregs in animal 
models have led to increased immune activation and high viremia (Cecchinato et al., 
2008, Pandrea et al., 2008), illustrating the importance of these cells in containing 
infection. Treg maintenance in non-progressive disease as shown in various studies 
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could explain the enhanced HIV specific function in those individuals (Chase et al., 
2008, Jiao et al., 2009, Seddiki and Kelleher, 2008). 
 
In HIV infection, Treg studies are limited by the need to first identify markers that 
reliably predict function since to date the expression of the markers does not 
necessarily predict function (Ford et al., 2009). Although controversial in HIV, the 
importance of these cells in HIV control requires further investigation, particularly in 
children where their abundance from infancy may be the reason for impaired CD4+ T 
cell mediated control. A study done in infant macaques in SIV infection strongly 
suggested active suppression of the CD4+ T cell response by Tregs, depletion of which 
resulted in enhanced SIV T cell responses that were comparable to those observed in 
adult macaques (Hartigan-O'Connor et al., 2007). Thus it is possible that the high Treg 
cell activity in infants may account for the general lack of viral control to pathogens 
and low reactivity to vaccines in perinatal HIV infection. Alteration of Treg cell 
function through interventional studies might be important to improve infant T cell 
control and response to vaccinations (Hartigan-O'Connor et al., 2007). More studies are 
also needed to understand innate immune responses in children since this arm may be 
more important in children who don’t have a well developed adaptive immune system. 
 
While adaptive T cell responses are quick to develop, humoral responses on the other 
hand can take up to months to develop following infection, but once detectable are 
known to be well maintained. A successful HIV-1 vaccine would ideally elicit effective 
long lasting immune responses consisting of both neutralizing antibodies and CD8+ T 
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cell responses that recognize diverse strains of the virus and that can also protect at 
possible sites of infection (Fauci et al., 2008, Haynes and Shattock, 2008). 
Theoretically, neutralizing antibodies would have a prophylactic effect to prevent 
infection at mucosal sites, while CD8+ T cells would have a therapeutic effect at 
controlling viral load and slowing disease progression in cases where infection occurs 
(Munier et al., 2011).  Recent advances in the vaccine field identified new monoclonal 
antibodies and demonstrated that broad neutralizing antibodies for multiple HIV-1 
clades can be made (Walker et al., 2009, Wu et al., 2010). However, the challenge is 
that these antibodies are not easily induced in HIV-1 infection or by current vaccines 
(Haynes et al., 2010).  
 
For example, the RV144 Thai trial that offered new hope that a preventative HIV-1 
vaccine is possible did not induce neutralizing antibodies. The neutralizing antibodies 
induced by the vaccine regimen were of low titre and did not have broad specificity 
against heterologous strains (Rerks-Ngarm et al., 2009). Thus the correlate of 
protection for the modest level of protection is still unclear at this stage. There has been 
speculation that protection may have been mediated by some short-lived antibody 
response as considerable titres of binding antibodies to Env were induced. Antibodies 
that mediate antibody dependent cellular cytotoxicity (ADCC), antibodies that mediate 
other Fc receptor mediated antiviral activities such as induction of β-chemokines or 
IgM or IgA antibodies that inhibit virus movement across mucosal barriers and 
traditional neutralization antibodies are all being considered in the investigation to 
understand correlates of immunity of the vaccine regimen (Haynes et al., 2010, Munier 
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et al., 2011). Although our data suggests that immune-mediated viral attenuation, level 
of T-cell activation and T-cell functionality can impact on paediatric HIV disease 
progression; other mechanisms of immune control such as the ones proposed for the 
RV144 have not been comprehensively studied in children and should form the basis 
for future work.  
 
Despite efforts to combat mother-to-child-transmission through administration of 
HAART, transmission is still inevitable as most women present late at antenatal clinics. 
Thus there is still a need for a vaccine that can prevent perinatal transmission. The 
ability to mount immune responses by the majority of intra-uterine infected infants in 
our cohort offers hope that most infants could benefit from a vaccine that prevents 
intra-uterine infections in those unfortunate cases. The differences observed in the 
specificity of the generated immune responses between infants and adults in our study 
setting may account for the lack of immune control in infants, thus our studies suggest 
that an ideal paediatric vaccine would need to be engineered to induce T cell responses 
of the right specificity that can mediate control from early life.  However, our studies 
do not rule out that beyond T cell protein specificity there are other mechanisms 
mediating poor viral control by children. Further studies will be needed to address what 
specific immune defects they may have that may contribute to their inability to control 
HIV.  
 
In an attempt to partially address these potential defects of CD4+ and CD8+ T cells in 
children, we simultaneously assessed T cell polyfunctionality, activation and 
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senescence in a small group of slow and rapid progressor children either undergoing 
ART or not as part of a pilot study. Our findings need to be interpreted with caution, as 
they might not represent the natural course of disease without ART and involved only 
small numbers of children. While the sharing of escape mutations between mother and 
child can be disadvantageous to the child, our data demonstrated that infants can benefit 
from acquisition of a less fit virus as has been demonstrated in adults. Larger studies in 
treatment naïve children are necessary to confirm our findings of T cell function and 
also further investigate viral and host factors that render the virus less replicative. 
Taken together, our studies of T cell function and HIV replicative fitness may help as 
laboratory markers in predicting disease outcome in children and in their clinical 
management in cases where ART is stopped or cannot be implemented. These data also 
suggest that immune-driven viral attenuation can impact on HIV clinical outcome in 





Without antiretroviral treatment, the majority of children progress very rapidly to 
disease following HIV infection. However, a small subset of children can control virus 
replication for years without the need of ART. These series of studies examined the 
contribution of virus specific CD8+ T cells to relative control of viral replication and 
disease progression in paediatric HIV-1 infection. We illustrate for the first time using a 
cohort of infected children that CD8+ T cell responses are mounted in the first days of 
life in most in-utero infected infants and that the lack of viral containment in most 
children during infancy is not due to the inability to induce CD8+ T cell responses. 
Rather, we show that the specificity of the CD8+ T cell response is different in 
comparison to acute adult infection, and could thus explain the rapid progression noted 
in infants. Furthermore, we show that the polyfunctional effector phenotype of the 
CD8+ T cell response rather than IFN-γ measurement alone, together with reduced 
immune activation and reduced T cell senescence may determine slow progression in 
paediatrics. Finally, we demonstrate that as in adults, the targeting of Gag epitopes 
presented by protective HLA alleles in either the mother or child can impact on viral 
fitness and disease outcome in the child. 
 
The failure of past vaccines may in part be explained by insufficient knowledge of 
correlates of immune protection and inadequate assays to evaluate such responses 
(Walker and Burton, 2008). Whereas a lot of effort has been made to define these 
mechanisms in adults, differences in disease manifestations between adults and 
children might require manipulation for success in vaccine interventions in children. 
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However, it is encouraging that there are some similar mechanisms in paediatrics and 
adults with regards to viral control. Further assessment of these mechanisms will 
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